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ABSTRACT
Fadnavis, Rucha M.S., Department of Pharmacology and Toxicology, Wright State University, 2017.
Effect of hyperglycemia and thiazolidinediones on cardiac angiotensin converting enzyme 2 (ACE2) and
neprilysin (NEP) in db/db diabetic mice.

Type 2 diabetes mellitus is strongly associated with increased risk of cardiovascular disease. Despite
availability of several antidiabetic medications, the cardiovascular outcomes remain unchanged. Activation
of renin angiotensin system is one of the critical factors in development of diabetic complications.
Hyperglycemia causes an increase in tissue and circulating Angiotensin II. Angiotensin converting enzyme
(ACE2) and neprilysin (NEP) are angiotensin (1-7) forming enzymes. ACE2 was first cloned from heart
failure patients and has cardioprotective and renoprotective properties. Combination of angiotensin receptor
antagonism and NEP inhibition is a new therapeutic strategy for treatment of heart failure. The aim of this
study was to investigate whether there is an alteration of cardiac NEP and ACE2 in db/db mice and to study
the effect of glycemic control with rosiglitazone and pioglitazone on these enzymes. Lean control and db/db
mice were fed 20 mg/Kg/day rosiglitazone and pioglitazone. Diabetic mice demonstrated hyperglycemia
which was attenuated by rosiglitazone and pioglitazone treatment. Western blot revealed two bands for
NEP and ACE2 in both lean and db/db mice in both the studies. Mature NEP was downregulated while
fragment was upregulated in db/db mice. Expression of mature ACE2 was upregulated in db/db mice while
the fragment was not affected. Both rosiglitazone and pioglitazone had no effect on cardiac NEP and ACE2
expression. There was a significant increase in cardiac ADAM 17 expression in db/db mice. Another aim
was to optimize the fluorescence based enzyme activity assay for renal and cardiac ACE2 and NEP.
Protease inhibitors for prolyl endopeptidase, prolyl carboxypeptidase, aminopeptidase A-M were
introduced in the assay buffer. Addition of protease inhibitors improved the specificity of the renal ACE2
activity assay. Protease inhibitors however, did not affect renal NEP activity assay. This is the first study
to report the presence of two immunoreactive bands for cardiac ACE2 and NEP expression. We also report
the possibility of fully mature form of cardiac NEP being degraded to form fragmented form. To the best
of our knowledge, this study is also the first to report an upregulation in cardiac ACE2 in db/db mice.
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I. INTRODUCTION

Diabetes Mellitus

Scientific research throughout the 19th and 20th century has led to rapid advancement in drug discovery
and better healthcare practices. The average lifespan has risen due to the decline in mortality caused by
infectious diseases. On the flip side, lifestyle diseases have been an emerging trend since late 20th century
and are rapidly rising. Among these lifestyle diseases, diabetes mellitus is one of the biggest health
challenges. Diabetes mellitus is a chronic disease associated with increased morbidity and mortality
syndrome of metabolic disorders that is most commonly associated with impaired glucose processing.
Diabetes mellitus is manifested in many forms namely prediabetes, type 1 diabetes, type 2 diabetes,
gestational diabetes, neonatal diabetes, monogenic diabetes syndrome, cystic fibrosis induced diabetes and
post transplantation diabetes (1). Type 2 diabetes mellitus (T2DM) is the prevalent form of diabetes in
patients, about 98% of diabetic patients suffer from T2DM. T2DM is characterized by impaired glucose
tolerance, insulin resistance by target organs and relative reduction in insulin secretion by pancreatic cells leading to hyperglycemia (1). Diabetes control and complications trial (DCCT) and the United
Kingdom Prospective Diabetes Study (UKPDS) showed that risks and complications in diabetic patients
are directly related to glycemic control as measured by glycated hemoglobin (HbA1C) levels (2). Effective
treatment of hyperglycemia of type 2 diabetes is of critical importance in management of macrovascular
and microvascular complications.

Epidemiology

Worldwide projections by the International Diabetes Federation number of patients suffering from diabetes
51% by 2030 (3;4). Diabetes is prevalent in 10% of total adult population of North America. According to
the National Diabetes Statistics Report, 7.6% of non-Hispanic white, 9.0% of Asian American, 12.8% of
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Hispanic, 13.2% of non-Hispanic black and 15.9% of American Indians/Alaskan Native populations suffer
from some form of diabetes (5). The number of patients suffering from diabetes is projected to grow by
98% (4). Growing number of patients concurrently leads to increase in healthcare expenditure which is
currently projected to around 612 billion USD and 1010 billion USD (3). The enormous costs associated
with treatment is an enormous burden on the economy. It is important to study the pathophysiological
mechanisms of type 2 diabetes to devise effective strategies for diagnosis, treatment and management of
diabetes complications.

Risk Factors for Type 2 Diabetes

Figure 1: Interaction between various risk factors and condition of prediabetes and type 2 diabetes.
Modified from Chatterjee et. al 2016 (6)
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Multiple genetic and lifestyle factors contribute towards the development of type 2 diabetes (7). It has thus
been characterized as a polygenic disease (7). According to the guidelines provided by the American
Diabetes Association, family history, lack of physical activity, hypertension, obesity (BMI 25Kg/m2),
dyslipidemia, polycystic ovary disease, low testosterone are the most common risk factors that lead to
prediabetic state (8). Prediabetic state is usually asymptomatic and thus patients with any of the
aforementioned conditions have been advised to undergo regular screening tests for type 2 diabetes after
age of 45 years (8).

Diagnosis of Diabetes

Diagnostic criteria for the diagnosis of diabetes are elucidated in the guidelines provided by the American
Diabetes Association (9). Since patients do not always exhibit classic symptoms of hyperglycemia, a variety
of criteria have been set by the advisory committee of the American Diabetes Association. One of the
following criteria need to be fulfilled for appropriate diagnosis:
1. A fasting plasma glucose  126mg/dL, where fasting plasma glucose is defined as having no
food intake at least 8 hours prior
2. Plasma glucose levels  200 mg/dL in an oral glucose tolerance tests, performed according to
the World Health Organization guidelines with a glucose load of 75g anhydrous glucose
solution in water
3. Glycosylate hemoglobin (HbA1C)  6.5% in an National Glycohemoglobin Standardization
Program (NGSP) certified standardized laboratory test. Random plasma glucose  200mg/dL
in a patient with classic symptoms of hyperglycemia.

However, progressive organ damage leads to severe complications until proper diagnosis of type 2 diabetes
in most patients. This organ damage takes place through several pathophysiological mechanisms.
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Pathophysiology of Diabetes Mellitus

Figure 2: Pathophysiology of type 2 diabetes mellitus.
Patients with type 2 diabetes require excessive levels of plasma insulin. Rise in blood glucose levels
stimulate production of insulin from the pancreas. The insulin normally produced fails to stimulate the
muscle and liver. This results in reduced glucose uptake from the blood. The liver contributes to high
glucose levels by breaking down and releasing stored glucose (glycolysis) and, to a lesser extent, making
new glucose (gluconeogenesis). Some of the excess glucose is taken up by the fat cells or taken up by the
liver and converted to triglycerides. Accumulation of excess triglycerides lead to lipotoxicity.
Hyperglycemia in turn leads to impaired mitochondrial function, reactive oxygen species (ROS)
production and renin angiotensin system (RAS) activation.
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To reduce the impact of diabetes on lives and the economy, it is important to understand the underlying
pathophysiological mechanisms leading to complications of diabetes. Although insulin resistance and beta–
cell dysfunctions are the main drivers for type 2 diabetes, other factors also contribute to the pathogenesis
of the disease.

(i) Hyperglycemia

Circulating levels of blood glucose are significantly elevated in patients with type-2 diabetes. Higher levels
of glucose in the blood are associated with generation of reactive oxygen species (ROS) , cytokine
activation, a decreased expression of glucose transporter type (GLUT) receptors and increased production
of advanced glycated end-products (AGEs)(10). Role of hyperglycemia in the development and progression
of renal dysfunction in type 1 and type 2 diabetes was demonstrated in experimental animals previously in
our laboratory(11;11-13). In this study, the focus will be on the effect of hyperglycemia on cardiovascular
system.

(ii) Hyperinsulinemia

Type 2 diabetes mellitus is characterized by insulin resistance in the target organs mainly muscle and liver
(14). Insulin has a significant influence on glucose transport, glycolysis, glycogen synthesis, cardiac
hypertrophy, protein synthesis and lipid metabolism (15;16). Additionally, insulin participates in the
regulation of myocardial contractility (17) and offers protection against ischemic myocardial death (18),
autophagy (19) and cell survival directly or via IGF-1 action. Hyperinsulinemia starts a chain of
pathophysiological events that lead to obesity (20).

(iii) Reactive oxygen species (ROS) and oxidative stress

Nitric oxide is endothelium derived relaxing factor (EDRF), which acts an endogenous vasodilator (21).
Loss of endothelial nitric oxide biosynthesis has been observed in diabetic patients (22). ROS are produced
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in the vasculature of diabetic patients by sources like endothelial nitric oxide oxidase, cytochrome 450,
mitochondrial electron transport chain and many others (23). Hyperglycemia increases production of
superoxide ion through the mitochondrial electron transport chain (24;25). Formation of AGEs are also
implicated in formation of ROS in hyperglycemia induced cellular injury to cardiomyocytes (26). Increased
production of AGE products is a result of oxidation of protein and lipids along with their enzymeindependent glycation (24;25).

(iv) Lipotoxicity

Metabolism of glucose and free fatty acids (FFAs) contribute to energy production in most tissues of the
body (23). Hyperglycemia and increased levels of plasma triglycerides are characteristic of T2DM (27).
Glucose transport is suppressed in the myocardium in diabetic state as a downstream effect of insulin
resistance (27). Therefore, FFAs act as the primary substrates for energy production and result in
lipotoxicity (27). This lipotoxicity is a result of accumulation byproducts of excessive FFA metabolism
(27). Lipotoxicity has been found to cause an increase in calcium in the cytoplasm which might led to
ventricular stiffness in diabetic cardiovascular disease (27;28).

(v) Impaired mitochondrial function

Mitochondrial production of energy in any cell of the body is a chief source for ATP generation (29). The
number of mitochondria is higher in cardiomyocytes compared to other tissues in the body (29). Due to the
high oxygen demand in the cardiomyocytes, the heart muscle is rendered vulnerable with small amount of
mitochondria damage (29). Substantial research demonstrates that the mitochondrial function is impaired
in the cardiomyocytes in type 2 diabetes (29;30) in the myocardium of patients with type 2 diabetes. There
is severe mitochondrial dysfunction in rodent models of type 1 and type 2 diabetes (31;32). Human studies
have also confirmed the impaired ability of cardiomyocytes (27) and the resulting decreased ATP
generation.
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(vi) Activation of Renin Angiotensin System (RAS)

Activation of RAS has been implicated in development of impaired endothelial dysfunction, vascular
inflammation and prothrombotic state (33). Enhanced expression of Angiotensin converting enzyme (ACE)
and subsequent Angiotensin II (Ang II) is associated with atherosclerotic disease in patients (34). Increased
ACE was observed in patients with acute coronary syndromes (35). Resulting oxidative stress due to
upregulation of RAS in the cardiomyocyte and endothelial cells in diabetic patients leads to various
conditions like ventricular dysfunction and fibrosis (36). RAS inhibition by with ACE inhibitors like
enalapril in several clinical trials has shown significant improvement in cardiovascular symptoms (37-39).
Thus modulation of RAS is a cornerstone in the management of cardiovascular symptoms in patients with
type 2 diabetes.

Complications of Diabetes

Deleterious effects of impaired glucose handling due to type 2 diabetes are seen in various organs (8). Preexisting diabetes has been to found to increase risk of certain types of cancers, cardiovascular disease,
kidney disease, neuropathic disorders, cognitive decline, fatty liver disease, bone disease, reproductive
dysregulation and psychological disorders (8). Among all these complications, cardiovascular disease and
kidney disease are one of the major complications that are associated with burdensome management and a
huge cost to the economy (8).

(i) Cardiovascular Complications

Damage to the cardiovascular system by glucose dysregulation is a major complication of diabetes (40).
Cardiovascular complications are the top cause of morbidity in type 2 diabetes mellitus patients(41)(42).
Diabetic cardiomyopathy was first described by Rubler et al in 1972 as a distinct condition after studying
etiological factors in heart failure patients (43). Cerebrovascular disease, cardiovascular abnormalities,
7

nephropathy and peripheral neuropathy are the most commonly associated complications with type 2
diabetes (44)..

Human and rodent studies establish diabetic cardiomyopathy being chiefly associated with left ventricular
dysfunction (45;46). Associations between hyperglycemia and microvascular and macrovascular
complications of diabetes were found in diabetes complications and complications trial (DCCT) and other
trials (8). The Framingham study with 5,209 men and women with pre-existing diabetic condition were
found to be associated with increased risk for congestive heart failure over 18 years of follow-up (47). There
is a marked increase in incidence of cardiovascular conditions like heart failure, coronary heart disease in
patients with pre-existing diabetic condition (29;47). Diastolic dysfunction in diabetic and hypertensive
patients was associated with aortic stiffness (48).

The cardiovascular complication in patients with type 2 diabetes have been characterized by structural and
functional changes (27). Structural changes are characterized by left ventricular hypertrophy (LVH)
(49;50) in male and female patients with type 2 diabetes as seen in various studies (47;51). Chronic
hyperglycemia and insulin resistance was found to be associated with increased left ventricular mass (52)
(53). Myocardial fibrosis and collagen deposition was found in patients with diabetes without pre-existing
condition of hypertension and coronary artery disease (54). Thickening in blood vessel walls like capillaries
and hypertrophic increase in size of cardiomyocytes is observed in diabetic patients with no apparent
symptoms of cardiovascular disease (55). Collagen type I and III deposition was observed in biopsy samples
from both right and left ventricles of type 2 diabetic patients (55). Patients with type 2 diabetes without preexisting conditions like hypertension and coronary artery disease seem to demonstrate the interstitial
fibrosis and collagen deposition (55-57). Increased levels of myocardial triglycerides are also found to be
present in type 2 diabetes patients with cardiovascular symptoms (58). Cardiovascular disease symptoms
are manifested as early diastolic dysfunction followed by subsequent systolic dysfunction (59). Low
contractile reserve due to reduced ability in raising ejection fraction has also been found to be associated
with diabetes-induced cardiovascular disease (27;60).
8

(ii) Diabetic Kidney Disease (DKD)

Diabetes is one of the most common causes of chronic kidney diseases, and accounts for about 50% of
cases for end-stage renal disease in developed countries (61). However, damage to the kidney structure and
function is too severe till the time it gets detected with the help of existing diagnostic criteria (62). The
cardiovascular risks associated with kidney diseases are compounded by conditions like diabetes,
hypertension atherosclerosis, arteriosclerosis, abnormal sympathetic stimulation to the heart and structural
heart defects (61;63). Alteration of RAS components in diabetic patients and various mouse models has
been found to be a critical factor in the development of renal dysfunction and eventual ESRD (64). The
current study will investigate the effect of hyperglycemia and pharmacological therapy on alteration of
cardiac RAS system.

Management of Diabetes

Guidelines from the American Diabetes Association elucidate the recommended therapies and
pharmacological interventions for the treatment of patients with T2DM. The recommendations encompass
normalizing blood glucose levels, management of cardiovascular risks through lifestyle and
pharmacological interventions (65).

(i) Lifestyle Modification

For effective management of type 2 diabetes modifications in diet to include healthier, fiber rich nutritious
food is the most important recommendation by the American Diabetes Association (8). Diabetes-specific
medical nutritional therapy is catered to each patient for inclusion of proteins, fats, carbohydrates, fiber in
a balanced fashion to make up a food plan (8). Along with modifications in diet, physical exercise has also
been an effective tool for management of diabetes based on several clinical trials (66). Aerobic exercise has
been shown to increase energy demand, thus showing improvement in glycemic control and lipid
parameters (66). Improvement in insulin sensitivity and significant weight loss has been observed with
9

intense exercise (67). Release of irisin has been found to convert unhealthy white adipose tissue to healthier
brown adipose tissue after exercise (68). Resistance exercise increases muscle strength, increase bone
mineral density, increase lean muscle mass leading to improved glycemic control and improvement in
insulin sensitivity (69;70). Previous work in our laboratory has demonstrated the benefits of physical
exercise in normalizing hyperglycemia and attenuation of albuminuria in db/db diabetic mice (11).

(ii) Pharmacological Intervention

Monotherapy with metformin is the front-line treatment for type 2 diabetes (8). Metformin is safe, cost
effective and has been found to decrease risk of cardiovascular events (8;71). However, long term treatment
with metformin has been found to cause vitamin B12 deficiency and anemia (8). Dual therapy with
metformin has been recommended with a diverse class of drugs for patients who need better glycemic
management. Those class of drugs are sulfonylureas, thiazolidinedione, dipeptidyl peptidase 4 (DPP-4)
inhibitors, SGLT2 inhibitors, glucagon like peptide 1 (GLP-1) receptor agonists and insulin in high risk
patients (8). Triple therapy of metformin with a combination of two classes of drugs mentioned before is
recommended in patients whose diabetic symptoms do not get controlled with mono or dual therapy (8).

Despite the availability of numerous medications for treatment of diabetes, none to few are free of sideeffects. There is a surprising lack comparative analysis among the antidiabetic medications about their side
-effects. Thiazolidinedione are peroxisome proliferator activating receptors  (PPAR) agonists have been
extremely successful in management of hyperglycemia. These have recently have come under scrutiny for
associated cardiovascular risks and increased mortality. We studied the effect of rosiglitazone and
pioglitazone in db/db diabetic mice.
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Peroxisome proliferator activating receptors 

Peroxisome proliferator activating receptors (PPARs) belong to a family of nuclear transcription factors
consisting of isoforms like PPAR , PPAR/δ and PPAR (72;73). After entering the nucleus, heterodimer
formation takes place with retinoid X receptor as a result of binding with ligands specific to PPARs and
thus they regulate gene expression (72). The different isoforms are expressed in various organs and activate
three different type of genes and thus perform different functions in the biological system (74). Several
studies have established PPAR  as one of the crucial modulator in the pathogenesis of diabetes (29).

Fat-specific adipocyte protein 2 (FABP), FA-binding protein, acyl-CoA synthase, glucokinase, and glucose
transporter type 4 (GLUT4) are gene targets of PPAR 𝛾. Moreover, PPAR-𝛾 also regulates genes involved
in insulin signalling and the expression of pro-inflammatory cytokines, such as tumor necrosis factor(TNF-) 𝛼 [6, 41]. PPAR𝛾 is a cellular target for the antidiabetic thiazolidinediones (TZDs), which sensitize
cells to insulin and improve insulin activity to improve glucose uptake in hepatocytes and skeletal muscles
(74-76). Expression of PPAR  is upregulated in diabetic rats (77;78).

PPARγ has a relatively lower expression in the heart when compared to adipocytes or kidneys (79).
Alteration in the expression of PPARγ from in-vitro studies and in-vivo studies has been implicated in
cardiovascular conditions like atherosclerosis, hypertension and ischemic injury to the heart (80;81).
Rosiglitazone, a PPARγ agonist demonstrated cardioprotective in OLEF rat model of diabetes mellitus via
suppression of cardiac fibrosis with a concurrent improvement in diastolic heart function (82). There was a
decrease in the receptors of advanced glycated end products (AGEs) heart tissues along with reduction with
connective tissue growth factor (82). Pre-treatment with pioglitazone in patients of type 2 diabetes with
acute myocardial infarction demonstrated improvement due to better rate of perfusion and a reduction in
cardiac reperfusion injury (83).
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(i) Thiazolidinediones: PPAR agonists in treatment of diabetes

Thiazolidinediones are called `insulin sensitizers’ as they reduce circulating plasma levels of insulin as a
result of improved uptake in the myocytes and adipocytes so that glucose regulation is improved.
Thiazolidinedione demonstrated beneficial effects in decreasing insulin resistance and overall improvement
in steady state glucose levels, plasma triglycerides and insulin levels in 1983 (84). Ligand binding assays
performed in adipocytes cells derived from mouse embryo line established selective agonism for the PPAR
 (85). These class of anti-diabetic agents are called anti-hyperglycaemic agents as they normalize the
elevated glucose levels with low risk of hypoglycemia. Use of thiazolidinediones demonstrated significant
lowering in glycosylated hemoglobin (HbA1C) ~1% (86). The randomized ADOPT trial comparing
rosiglitazone, metformin or glyburide in about 4,500 patients concluded rosiglitazone showed better
outcomes in stabilizing steady state glucose levels than metformin, a first line drug in antidiabetic therapy
(87).

(ii) Rosiglitazone & Pioglitazone

Rosiglitazone has been a prominent member of the thiazolidinedione class of drugs in management of
diabetes since its entry in the market in 1999 (88). Comparative analysis in ADOPT trial with glyburide
and metformin demonstrated better maintenance in glycemic control with rosiglitazone (89). Treatment
with rosiglitazone showed increased sensitivity of insulin in skeletal muscles, adipocytes and liver (90),
plasma blood glucose is subsequently reduced due to improved glucose uptake by skeletal cells, adipocytes
and liver, decreased endogenous gluconeogenesis (90)(91). Diastolic and systolic blood pressure was also
lowered in patients with rosiglitazone treatment (91). However, myocardial triglyceride levels were largely
unchanged with therapy with a possible increase in low density lipoproteins (LDLs) (92).

ADOPT trial also showed rosiglitazone to be beneficial in treatment of renal diseases associated with type
2 diabetes(89). Rosiglitazone treatment demonstrated inhibition of collagen IV deposition in primary mouse
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podocyte cultures(93). The AT1-ROS pathway is inhibited with the use of rosiglitazone (93). Rosiglitazone
attenuates renal injury in hepatic pancreatitis model (94). Previous studies in our laboratory have found
attenuation of hyperglycemia, albuminuria and renal fibrosis with rosiglitazone treatment in db/db diabetic
mice (95).

A meta-analysis study in 42 trials with 24 weeks of rosiglitazone treatment found association between
increased risk of myocardial infarction and other cardiovascular complications (96). This led to safety
concerns being associated with rosiglitazone treatment and led to its ultimate withdrawal from the market
(97). A large cohort study called the RECORD trial was conducted on FDA advisory committee
recommendation was inconclusive about any increase in cardiovascular risk with the use of rosiglitazone
(98;99). However, rosiglitazone has been banned in Europe and it sold in the US market with a caution
advisory on the label (100). The FDA since then has imposed stricter regulation for antidiabetic medications
where in addition to control of hyperglycemia, a low cardiovascular risk should be demonstrated (101).

Pioglitazone is another PPAR- agonist in the class of thiazolidinedione approved for oral monotherapy
for diabetic patients in 2002 (102). The PROactive trial evaluated the role of pioglitazone in reducing CVD
risk in diabetic patients (103). There was no significant decrease in CVD risks like overall mortality,
myocardial infarction and stroke but there was a significant decrease in patients with previous incidences
of myocardial infarction (101). A significant decrease in recurrent stroke incidence was also observed in
patients with previous stroke (101). A comparison between rosiglitazone and pioglitazone demonstrated
that while there is no significant increase in cardiovascular risks with rosiglitazone (101). Pioglitazone has
demonstrated mild cardioprotective properties along with normalizing hyperglycemia.

Pioglitazone has been suggested as a therapy for non-alcoholic steatohepatitis (NASH) (104). It has also
been useful in treatment of Parkinson’s disease (105;106). Pioglitazone is also useful in control of
atherosclerosis by its lipid lowering action (107). Besides normalizing hyperglycemia, pioglitazone also
has antibacterial properties and has shown improvement in cognitive function (108;109). There are still
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concerns of increased risk of congestive heart failure (CHF) and bladder cancer with pioglitazone use (100).
There needs to be a similar meta-analysis study for pioglitazone like that of rosiglitazone to make better
comparisons. In the present study we have used both rosiglitazone and pioglitazone to normalize glycemia
to investigate whether thiazolidinediones alter the balance of cardiac RAS.

(iii) Safety Concerns of Thiazolidinediones

Concerns have been raised about Thiazolidinediones causing water retention leading to peripheral edema
in the extremities (110). Patients with symptomatic heart failure are not able to tolerate Thiazolidinediones
due to concerns about exacerbation of heart failure and thus are contraindicated in these patients (110).
Fluid retention was observed with monotherapy and also with combination therapy (110). However, fluid
retention was managed with the use of diuretic therapy and thus no increase in mortality was observed
(111). Cardiotoxicity of high doses of rosiglitazone has been found to be independent of PPAR- actions
and associated with mitochondrial damage and dysfunctions (112). In-vitro studies show that
thiazolidinediones associated with lipid deposition in cardiomyocytes (113). Pioglitazone however, is
useful in lowering lipid levels in patients but has no demonstrated beneficial effect on echocardiographic
parameters of heart function (114). One of the frontline approaches for treatment of cardiovascular
complications in patients with or without diabetes is RAS inhibition. We thus aim to compare and contrast
the effects of rosiglitazone and pioglitazone on the cardiac RAS system in db/db diabetic mouse model.

Evidence of RAS activation in Diabetes related cardiovascular complications

Activation of RAS through the sympathetic nervous system has been strongly linked to cardiovascular risks
associated in patients with diabetes (115). Cardiac fibrosis (116;117), cardiomyocyte atrophy (117),
atherosclerosis (118;119) lead by diabetic hyperlipidemia are the pathological manifestations of this RAS
activation.
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Guidelines provided by American Diabetes Association (120) reference ACE inhibitors and Angiotensin
type 1 (AT1) receptor blockers as the front-line treatment for patients with existing diabetic condition at
high risk of developing cardiovascular complications. In diabetic patients with atherosclerotic
cardiovascular disease (ASCVD), RAS modulators like Angiotensin receptor blockers and ACE inhibitors
attenuate albuminuria, lower blood pressure, normalize albumin-to creatinine ratio to indicate slowing
progression of kidney disease. RAS modulation is thus a very important component of management of
diabetes and its renal and cardiovascular outcomes.

In this study we aim to study the effect of diabetes on the RAS components in the heart of db/db diabetic
mice. As there are concerns of increased cardiovascular risk with the use of thiazolidinediones, we also
investigated the effect of rosiglitazone and pioglitazone on cardiac RAS components in these mice.

Components of Renin Angiotensin System (RAS)

Many successful therapeutic strategies for control of diabetes related cardiovascular disease employ
modulators of the RAS. Improper activation of the RAS is linked to diabetes, hypertension and organ
damage. All of these are identified as a major cause of chronic kidney diseases (121;122). RAS is a major
component in the physiological control of blood pressure and fluid equilibrium in the human body. In
response to lowered blood perfusion of blood, a peptide renin is released from the Macula Densa cells
located at the juxta-glomerular cells in the kidney. Renin cleaves angiotensinogen to form Angiotensin I.
This Angiotensin I is cleaved by Angiotensin converting enzyme (ACE) to form Angiotensin II (Ang II).
Ang II is the major active component of the RAS having a powerful effect on the arterial pressure
regulation, natriuresis and cell proliferation. The acute effect of Angiotensin II on arterial pressure is
primarily by renal vasoconstriction which then leads to enhanced tubular sodium reabsorption (123;124).
Abnormally increased activity of Angiotensin II leads to elevated arterial pressure, increased sodium
reabsorption from proximal and distal tubules, proliferation, fibrosis and renal injury.
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Studies have shown that a low sodium diet causes a downregulation in ACE activity and subsequent lower
blood pressure. Upregulation ACE2, an enzyme that degrades Ang II to form vasodilatory Ang (1-7)
suggests that RAS system has its own homeostasis to maintain (125).

(i) Angiotensin converting enzyme 2 (ACE2)

The classical view of how the renin- angiotensin system works was revolutionized with the discovery of
ACE2 in 2000 by Donoghue et al and Tipnis et al (126;127). Structurally, ACE2 is roughly 42%
homologous to Angiotensin Converting enzyme (ACE). This enzyme is a carboxypeptidase that causes
cleavage of the Leucine amino acid residue at the C-terminal end of Ang I to form Ang (1-9). Further
studies show that is also involved in the formation of a biologically active renoprotective peptide Ang (17) by the degradation of Ang II (128;129). Various studies have demonstrated that ACE2 is catabolically
more active towards degrading Ang II rather than Ang I (128). Considering that Ang (1-7) plays a
renoprotective role due to its vasodilatory properties, ACE2 is a renoprotective enzyme. Studies have shown
an ADAM 17 mediated increased shedding of ACE2 in the urine of diabetic mice (130-132). This shedding
is ameliorated by exercise, insulin treatment and anti-hyperglyaemic agent rosiglitazone (130;133;134).
Urinary ACE2 activity in late stages of diabetes in diabetic mice is increased which was ameliorated with
the administration of insulin (135). It however, remains to be seen whether this decrease in ACE2 shedding
is due to control of glycemia or improvement in the kidney function. A recent study with Sprague Dawley
rats in a renovascular hypertension model has shown downregulation of ACE2 in the peripheral membrane
of both injured and contralateral kidney(136).

Studies with genetically deficient ACE2 mice demonstrate that release of ACE2 is critical for nitric oxide
(NO) and oxidative stress in the vascular endothelium (137). Deletion of ACE2 in streptozotocin-induced
diabetic rats exacerbates progressive glomerular and interstitial cell damage (138). Downregulation of
ACE2 is implicated in diabetic nephropathy and the injury to kidney tubules resulting from it (139). Cardiac
hypertrophy and cardiac remodeling was a consequence of increased Ang II levels and pressure overload
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in ACE2 knockout mice (140;141). Plasma soluble form of ACE2 is elevated in patients after an episode
of myocardial infarction (142). ACE2 plays a major role in the heart. ACE2 knockout mice have increased
Ang II levels intracardially along with reduction in cardiac contractility (143). In mice with myocardial
infarction an upregulation in matrix metalloproteinase-2 and 9 associated with loss of ACE2 was
demonstrated (144). This loss of ACE2 could also lead to neutrophil infiltration and subsequent
upregulation of inflammatory cytokines like IL-6, chemokine, interferon γ (144).

(ii) Neprilysin (NEP)

NEP, also known as neutral endopeptidase, enkephalinase or E.C. 3.4.24.11 is involved in the production
of Ang (1-7) from Ang I and from Ang (1-9) (145). It is a membrane bound enzyme and is a
metalloproteinase with the presence of zinc at its active site (146;147). It was originally isolated by Kerr
and Kenny from rabbit kidney brush border in 1974 where they found its ability to cause a cleavage in the
-chain of Insulin peptide (148). NEP is inhibited by the thermolysin inhibitor phosphoramidon (147).
Studies performed by Schwartz and his colleagues have shown NEP to be present in the brain and
categorized it as an enzyme causing cleavage of encephalin, it is thus called an enkephalinase (149). NEP
also helps in the degradation of Ang II and helps in the formation of Ang (1-7) (150) which has major
nephroprotective properties. Research conducted thereafter have demonstrated expression of NEP in a
variety of organs like brain, heart, kidney, lungs. NEP causes cleavage of its substrate at the amino side of
its peptide linkage (151). It is critical in the processing and breakdown of the vasoactive peptides that are
essential for salt and water regulation of the body, namely atrial natriuretic peptide (ANP) and brain
natriuretic peptide (BNP)(152). ANP enhances natriuresis and thus helps in regulating blood pressure along
with playing a role in diminishing hypovolemia by increasing water retention (153).
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(iii) Dual AT1 Receptor Blockade and Neprilysin Inhibition in Heart Failure

Inhibition of NEP/ ACE combined produced marked decrease in peripheral vascular resistance than with
ACE inhibition alone (154). This encouraged research to investigate dual inhibition of NEP/ACE as a
therapeutic intervention. However, this dual inhibition degrades bradykinin which increased the risk of
angioedema (155;156). Numerous trials CHARM-Preserved, PEP-CHF and I-PRESERVE failed to provide
better outcomes for heart failure patients (157-159). Dual inhibition of NEP enzyme with AT1 receptor
blockers has thus gained a lot of attention in the recent years. Sacubitril/ Valsartan (LCZ696) is the new
candidate for improving clinical outcomes in patients with heart failure. The 2012 PARAMOUNT trial
comparing overall outcomes for patients with heart failure using LCZ676 compared to valsartan showed
improved outcomes with decreased blood pressure (160). However, there was a rise in urinary albumin to
creatinine ratio, showing signs of kidney damage (161). LCZ696 was then tested for comparison with
Enalapril and was successful in providing better efficacy and heart outcomes in the PARDIGM-HF trial in
2014. The trial was stopped before completion because the drug candidate showed overwhelming data in
support if its efficacy and outcomes and fewer side effects when compared to the enalapril (162). As patients
with diabetes are one of the biggest demographics for cardiovascular episodes and heart failure, it is
important to understand whether there is an alteration in the expression and activity of cardiac NEP levels
in diabetes. One of the aims of this thesis is to investigate whether there is an alteration in cardiac NEP
levels in diabetes. Recent study of diabetic nephropathy induced by streptozotocin in mREN2 rats showed
a decrease in proteinuria and albuminuria using AT1 receptor blocker (irbesartan) and NEP inhibitor
(thiorphan) therapy compared to AT1 receptor blockade alone (163).
There is evidence of NEP downregulation in Alzheimer’s animal model studies. Combined NEP/ACE
inhibition improved femoral blood flow and femoral vascular conductance in male STZ induced diabetic
rats (164). Inhibition of NEP has been linked to an increase in insulin sensitivity (165;166). Plasma
concentrations of NEP are increased in obese and insulin resistant mice (167).
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As NEP is a multifunctional enzyme, it has different effects upon different organs of the body. One of the
most important effect is its role in the degradation of amyloid deposits in the brain. Neurofibrosis and
plaques in the brain autopsy of a patient were observed in 1905 by Alois Alzhemier. However, Alzheimer
was not able to characterize what the plaques were made from (168;168). These plaques are made of
amyloid- beta peptide which accumulate in the brain and cause neuronal cell loss which leads to
Alzheimer’s (169). Lentivirus linked overexpression of NEP in hippocampal cells showed that NEP inhibits
the neurotoxicity of amyloid beta peptides (170). The same authors also show that NEP might be involved
in slowing down the progression of Alzheimer’s disease (171). Adenovirus-mediated expression of soluble
form of NEP in the plasma inhibits deposition and aids in clearing up amyloid proteins in mouse transgenic
model (172). The same authors demonstrate that NEP expressed inside the skeletal muscles also causes a
reduction in Amyloid deposits in transgenic Alzheimer’s mouse model (173).Urinary and renal studies in
db/db diabetic mice showed active fragments of ACE2 and NEP in the urine. There is evidence of ADAM
17, a metalloprotease to be responsible for cleavage of ACE2 and NEP. This study aimed to study the
cardiac modulation of ADAM 17 in db/db diabetic mice.

(iv) A Disintegrin and Metalloprotease-17 (ADAM 17)
ADAM 17 or tumor necrosis factor-  (TNF-) converting enzyme (TACE) belongs to a family of proteins
composed of about 750 amino acids called as the disintegrins or metalloproteinases (174). These enzymes
play important roles in various organs by promoting cell adhesion and cell maturation. These enzymes
prevent formation of amyloid β-protein from its precursor protein and thus protective in Alzheimer’s
disease (174). However, the activation of epidermal growth factor receptor (EGFR) by these enzyme
promotes tumor formation in cancer studies (174;175;175). ADAM 17 plays an important role in the
ectodomain shedding of various enzymes by regulating the expression of TNF- (174). ADAM 17 is
responsible for release of membrane bound TNF- from the cell surface in a soluble form. (176;177).
ADAM 17 is expressed in heart, kidney, brain and skeletal muscles (178).
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It has been shown before that AngII treatment induces ADAM 17 and TNF- in mice models (179). There
is a reduction in symptoms of renal diseases like glomerular damage and renal fibrosis after Ang II infusion
in mice lacking TGF-α and those given a specific TACE inhibitor (180). Inhibition of ADAM 17 in murine
model of polycystic kidney disease ameliorated symptoms of kidney dysfunction (181). Previous studies in
our lab have shown increased renal ADAM 17 expression in db/db mice (182). ADAM 17 expression is
increased in the peripheral mononuclear cells (PMNC) in patients with congestive heart failure (183).
Upregulation of ADAM 17 was also observed in patients with myocarditis. In animal studies with short
hairpin RNA knockdown of ADAM 17 in rat model there was an attenuation in cardiac hypertrophy (184).
ADAM 17 is an upstream factor to several other metalloproteases in the development of cardiac
hypertrophy (185). Ageing and loss in elasticity of coronary arteries is associated with upregulation of TNF (186). One of the aims of the present study is to investigate whether there is an alteration in ADAM 17
in diabetic hearts.

Animal Model of Diabetes

Type 2 diabetes is characterized by progressive loss in pancreatic efficiency which leads to development of
insulin resistance. In these conditions, normal or elevated levels of insulin fail to produce an effective
response against hyperglycemia (187). Research on diabetes in mouse models is focused on complications
of diabetes in addition to hyperglycemia. There are several genetic models like polygenic and monogenic
models. There are also diet induced mouse models for type 2 diabetes. The polygenic mouse models are
KK mice (188), new Zealand obese mice (189) among many others. Monogenic mouse models include the
Lep ob/ob and Lep db/db mice. The ob/ob mice are deficient in the satiety factor leptin while the db/db
mice are deficient in the leptin receptor (190).

In db/db mice, the presence of a point mutation in the gene coding for leptin receptor renders this mouse
insulin resistant (191). This is accompanied by high circulating levels of both insulin and glucose (191;192)
(193). None of the mouse models above, are able to develop all of the complications of type 2 diabetes.
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However, the db/db mice demonstrated cardiovascular dysfunction (194;195), nephropathy (196),
retinopathy (197), hypertension (193) and cognitive decline (198). This mouse model is thus useful in
studying organ specific complications of type 2 diabetes like cardiovascular disease and diabetic
nephropathy. Previous studies in the lab have employed db/db and Akita mice model to study the RAS
system alteration in the kidney. In this project, db/db diabetic mice were used to investigate whether there
is an alteration of cardiac ACE2, NEP and ADAM 17. In addition, we will also investigate of the effect of
normalizing hyperglycemia with rosiglitazone and pioglitazone on these RAS candidates.
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II. HYPOTHESIS AND SPECIFIC AIMS

1.

Hypothesis

In diabetic db/db mice, there is an alteration in the balance of cardiac Ang (1-7) forming enzymes
NEP and ACE2. This alteration could be a result of upregulation in cardiac ADAM17. Treatment of
hyperglycemia with pioglitazone and rosiglitazone will normalize cardiac NEP, ACE2 and ADAM
17.

2.

Specific Aims

1. To investigate the effect of rosiglitazone on hyperglycemia and cardiac ACE2, NEP and ADAM
17 protein expression.
2. To investigate the effect of pioglitazone on hyperglycemia and cardiac ACE2, NEP and ADAM 17
protein expression.
3. To optimize the fluorescence based enzyme activity assay for cardiac and renal ACE2 and NEP.
The effect of rosiglitazone and pioglitazone will also be investigated on cardiac ACE2 and NEP
activity.
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III. SIGNIFICANCE

Most of the research investigating the physiological role of NEP has been focused on the brain and lungs.
Recently, with the introduction of new therapy combining NEP inhibition with RAS blockade there is an
emerging interest in studying role of cardiac NEP. Therefore, this study aims to elucidate the expression
and activity of cardiac NEP.

Despite its discovery from cDNA library of heart failure patients, there are limited studies examining the
effect of ACE2 in the heart. Patients suffering from type 2 diabetes are the largest demographic for heart
failure. Yet, there is very limited data on cardiac ACE2 in diabetic conditions. This study thus aims to
investigate if there is alteration of cardiac ACE2 in db/db diabetic mice.

Following a meta-analysis, there are reports of increased myocardial infarction and heart failure risk in
patients with rosiglitazone treatment. Safety concerns have been raised regarding contraindication for the
use of thiazolidinedione class in diabetic patients with symptomatic heart failure. This is due to reports of
fluid retention leading to increased cardiac pre-load. Therefore, this study aims to compare and contrast
rosiglitazone and pioglitazone in db/db diabetic mice.
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IV. MATERIALS AND METHODS

Experimental design

Male 6 week old BKS.Cg-Dock7m +/+ Leprdb/J: db/db diabetic mice and their age-matched controls were
purchased (Jackson Laboratories, Bar Harbor, ME, USA). Individual housing was provided to these mice
in plastic cages at room temperature with regular 12:12 hour light: dark cycle for 12 weeks. Free access to
water and standard 18% protein rodent chow was provided to these animals (Harlan Teklad, Madison, WI,
USA).

Treatment with Rosiglitazone

Mice were randomly assigned into 4 groups. They were: Lean control fed standard chow (n= 9), Lean
control fed rosiglitazone diet (n=7, 20mg/Kg/day, Envigo Teklad, Madison, WI, USA), db/db fed normal
chow (n=10) and db/db fed rosiglitazone diet (n=10, 20mg/Kg/day, Envigo Teklad, Madison, WI, USA)
for 7 weeks.

Treatment with Pioglitazone

Mice were randomly assigned into 4 groups. They were: Lean control fed standard chow (n= 10), Lean
control fed pioglitazone diet (n=7, 20mg/Kg/day, Envigo Teklad, Madison, WI, USA), db/db fed normal
chow (n=10) and db/db fed pioglitazone diet (n=10, 20mg/Kg/day, Envigo Teklad, Madison, WI, USA) for
10 weeks.

Body Composition Measurement

ECHO MRI absolute body composition analyzer (Houston, TX, USA) was used to study the body
composition of animals. The instrument was calibrated and body weight of each mouse was recorded.
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Mouse was then placed in a clear plastic cylinder and a plastic plunger was placed on top keep the mouse
in place. This was done to ensure a stable and reliable reading. This whole setup was then placed inside
before mentioned instrument and the measurements for the animal were recorded. The mouse was then
returned to its cage after recording the measurement. Readings were taken one week before treatment with
drugs and after 6 weeks after treatment.

Blood Glucose Measurement

Test Strips from FreeStyle Neo® Blood Glucose Monitoring System (Abbott, Santa Clara, CA, USA) was
used to measure blood glucose levels. Blood sample was collected by tail puncture method. The tail was
pricked with surgical scissors to make a minute cut and the drop of blood was placed on glucose test strips.
Blood glucose measurement was performed weekly between 10 am and midday, or at intervals thereafter
as indicated. Blood glucose concentration values were expressed in mg/dL.

Organs Perfusion

Mice were anesthetized with euthasol (Preparation: 50mg/ml, Dose: 1µL/g mouse) and the chest cavity was
exposed. A needle was inserted in the left ventricle wall and cold 1X PBS was perfused through the heart
using perfusion pump (Bio-Rad, Hercules, CA). A slit was made in the right ventricle of the heart to let the
blood flow out of the heart. 1X PBS was perfused till the organs become pale and all the blood runs out of
the body. Using the same perfusion pump, a solution of 4% Paraformaldehyde was perfused in the organs
for fixing them. The mice were then dissected and organs were collected and stored in 4%
paraformaldehyde at 4 ̊ C.

Immunohistochemistry

The previously perfused paraffin-embedded heart sections were de-paraffinised with 98.5% Xylene. The
sections were then rehydrated sequentially for 5 minutes each in 100%, 95%, 50% and 30% ethyl alcohol
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solutions. These sections were then rinsed with phosphate buffer saline (PBS) and distilled water. For that
purpose, the sections were boiled for 30 minutes within a solution of 10 mM sodium citrate buffer (pH 8.5).
Incubation with methanol was then performed for about 20 minutes at -20 ̊ C temperature. In order to avoid
any non-specific antibody binding, the sections were blocked with 3% normal donkey serum at 4 C
̊ for an
hour. Primary antibodies were diluted with 3% normal donkey serum. The sections were then incubated
with primary antibodies NEP (Goat anti-mouse, R&D, AF1123, 1:500), ACE2 (Rabbit anti-mouse, Sigma,
HPA 000288, 1:200) and ADAM 17 (Rabbit anti-mouse, Abcam, ab2051, 1:1000) overnight at 4 C
̊ . The
excess antibodies were removed by washing the sections thrice with PBS. Secondary antibody incubation
was then performed with respective Alexa fluor-488 conjugated (Fisher Scientific, NH) and CY3
conjugated (Jackson Immunoresearch, West Grove, PA, USA) antibodies for signal amplification for 2
hours at 4 ̊C. The slides were mounted using a DAPI containing mounting medium (Vector Laboratories,
Burlingame, CA, USA).

Western Blot

Excised heart samples stored in dry ice were homogenized using bead homogenization method in Precellys
24 organ homogenizer (Bertin Corp., Rockville, MD, USA). EDTA-free lysis buffer was used to
homogenize the heart samples (Roche, NYC, NY, USA). Heart lysate samples were prepared for
electrophoresis by mixing 10g protein with a sample buffer solution containing -mercaptomethanol
(volume ratio 1:1). These samples were then separated using electrophoresis in a 8% sodium dodecyl
sulphate gel. The separated proteins were then transferred and blotted upon a polyvinylidine fluoride
(PVDF) membrane (Bio-Rad, Hercules, CA, USA). The membrane was then blocked with 5% milk solution
in 1XPBS+0.1% Tween 20 to avoid non-specific protein binding with the antibodies. The membranes were
then probed for specific protein detection using monoclonal and polycloncal antibodies such as: ACE2
(goat, R&D, 1:1000), NEP (goat, R&D, 1:1000), ACE (goat, Santa Cruz,1:500) and ADAM 17 (Abcam,
1:1000). The incubation with each of the primary antibodies was performed overnight. After washing
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excess primary antibody with 1XPBS+0.1% Tween 20 solution, these membranes were then incubated with
HRP-conjugated secondary antibodies like donkey anti-goat (R&D,1: 2000) and anti-rabbit (Santa Cruz, 1:
20,000). Membranes were incubated for 2 minutes with Immobilon chemiluminescent substrate (Millipore
Sigma, Bedford, MA, USA) and imaging was performed by exposing the membranes for specific times to
autoradiography films (Denville Scientific, Holliston, MA, USA) and developing the films in a dark room.

Optimization of ACE2 Activity

A quenched fluorogenic substrate called 7-Mca-APK (Dnp) (Biomol International, NY,U.S.A) was used to
measure the activity of ACE2. Cleavage by ACE2 enzyme of this substrate at the Dnp (2, 4 dinitrophenyl)
site develops fluorescence. This fluorescence had been quenched due to the presence of Dnp and cleavage
by ACE2 leads to development of fluorescence. ACE and ACE2 are very similar in their structure thus
specificity of the activity was ensured by addition of 10M Lisinopril, ACE inhibitor was used in the
reaction mixture. 10M of dual prolyl carboxypeptidase (PCP) and prolyl endopeptidase (PEP) inhibitor
ZPP, aminopeptidase A& M (AP-A & AP-M) inhibitors 5 M Amastatin and Bestatin respectively were
also added in the buffer. Whole kidney lysate (35 g protein) and heart lysates (35g) were incubated with
MLN-4760 (10mM, a gift from the former Millennium Pharmaceuticals, Cambridge, MA, USA) for 15
minutes at room temperature. Enzyme activity assay buffer with 0.01 M fluorogenic substrate was added
to the samples. The fluorescence thus developed was then detected at 328 nm excitation with the help of a
Biotek Synergy H1 plate reader. The results were recorded at 0, 0.5, 1, 2, 4, 8 and 24 hours. The results
obtained were then expressed in terms of Flu.Units/µg protein/hour

Optimization of NEP Activity

Enzyme activity for Neprilysin was measured using an indirect coupled enzyme assay method. 15 μg of
sample lysate and 4mM of Succinyl-Ala-Ala-Phe-7-amido-4- methylcoumarine substrate (Sigma Aldrich,
St.Louis, MO, USA) are allowed to incubate for an hour. This results in cleavage of fluorogenic substrate
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by NEP forming a hydrophobic residue. Subsequent incubation with 400mU of Leucine aminopeptidase
results in removal of phenylalanine residue to get 4-amido 7 methylcoumarine (AMC) which produces
fluorescence. NEP dependent activity was determined by decrease in rate of digestion due to addition of 1
μM of specific NEP inhibitor Thiorphan. Assay buffer was prepared using Tris buffer (pH 7.6) containing
0.05M tris, 0.15M NaCl, 10M Lisinopril and 5mM of Zinc Chloride. Additional inhibitors like 10M of
specific PCP/ PEP inhibitor, 5 M specific AP-A & AP-M inhibitors Amastatin and Bestatin were added
in the buffer respectively. This buffer was mixed with NEP substrate for 4mM final concentration. In a dark
96 well plate, substrate buffer mixture was added to each well containing 15 μg of heart tissue lysate. After
one hour incubation with samples, 4mU of Leucine aminopeptidase and 0.2mM Phosphoramidon was
added to each well. Fluorescence produced was measured at excitation/emission of 390nm/460nm after 15
minutes, 30 minutes and 1 hour after addition of Leucine aminopeptidase and Phosphoramidon using Biotek
Synergy H1 microplate reader. The results obtained were then expressed in terms of Flu.Units/µg
protein/hour.

Statistical analysis

Statistical analysis was performed using Graph pad prism 5.01 and Statistica software (v.10). All of

the

data was expressed as mean ± SEM. The differences in blood glucose, body weight, food intake, water
intake, absolute body fat, lean mass and total body water were assessed by repeated measures two-way
ANOVA followed by Bonferroni’s multiple comparison test. For more than two groups one-way and twoway ANOVAs were used. Unpaired student’s t-test was used to evaluate the differences between two
groups. A value of *p<0.05 was considered statistically significant.
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Table 1: Age dependent changes in metabolic parameters of lean and db/db mice

Animal Strain

Lean

db/db

Lean

db/db

Age

6

6

14

14

Group Size

7

6

7

6

Body Weight

20.80±0.5

34.92±1.8*

26.6±0.5

40.01±0.48*

Blood Glucose

105.42±17.7

382.6±21.9*

116.0±19.6

600.0±0.00*

Food Intake

3.42±0.2

8.31±0.3*

3.38±0.1

6.84±0.8*

Water Intake

8.06±0.2

26.98±2.9*

6.11±0.3

31.43±3.7*

Absolute body fat

2.43±0.4

20.1±1.1*

6.20±0.8

20.20±1.7*

Absolute lean mass

12.5±0.7

14.59±0.6

16.61±0.9

14.59±0.6

Total body water

12.53±0.7

12.65±0.5

12.70±0.7

12.9±0.5

Values represent mean± SEM *p<0.05 vs. age-matched lean control mice is considered statistically
significant.
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Table 2: Effect of rosiglitazone on plasma hormone and lipid parameters in lean and db/db diabetic
mice
Animal Strain

Lean

Lean+Rosi

db/db

db/db+Rosi

Age

9

6

6

6

Group Size

9

6

6

6

Duration

7

7

7

7

Plasma Insulin (ng/ml)

1.1±0.4

1.5±0.1

7.0*±0.3

2.2#±0.3

Plasma adiponectin (µg/ml)

2.1±0.08

1.2±0.1

4.9*±0.08

4.1#±0.4

Plasma leptin (ng/ml)

2.8±0.2

1.5±0.3

26.8*±4.4

56.18#±3.7

Plasma glucagon (ng/ml)

0.07±0.01

0.05±0.01

1.7*±0.03

0.4#±0.01

Absolute triglyceride
(mg/dL)

75.56±5.52

101.8±4.46

281.7*±15.77

89.65#±7.94

Plasma cholesterol (mg/dL)

94.14±4.61

82.35±11.27

157.3±13.32

168.5±6.15

Values represent mean± SEM *p<0.05 vs. age-matched lean control mice and #p<0.05 vs. age-matched
db/db mice considered statistically significant.
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Figure 3: (A) Blood glucose levels in lean and db/db mice fed chow with and without rosiglitazone.
Repeated measured two way ANOVA analysis with Bonferroni’s posthoc test demonstrated significantly
higher blood glucose in db/db mice (*p<0.001 vs. lean mice).Treatment with rosiglitazone significantly
attenuated hyperglycemia in db/db mice (#p<0.001 vs untreated db/db mice). (B) Body weight measurement
(g in lean and db/db mice chow with and without rosiglitazone. Repeated measured two way ANOVA
analysis with Bonferroni’s Posthoc test demonstrated higher body weight in db/db mice (*p<0.001 vs. lean
mice). Treatment with rosiglitazone significantly increased body weight in db/db mice (#p<0.001 vs.
untreated db/db mice). Data is represented as mean± SEM of group size (n= 6-7).
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Figure 4: (A) Food intake in (g) in lean and db/db mice fed chow with and without rosiglitazone. Repeated
measures two way ANOVA analysis with Bonferroni’s posthoc test demonstrated higher food intake in
db/db mice (*p<0.001 vs. lean control). Treatment with rosiglitazone has no effect on food intake of db/db
and lean mice. (B) Water intake in lean and db/db mice chow with and without rosiglitazone. Repeated
measured two way ANOVA analysis with Bonferroni’s posthoc test demonstrated increased water intake
in db/db mice (*p<0.001 vs. lean mice).Treatment with rosiglitazone showed a significant decrease in water
intake of db/db mice (#p<0.001 vs untreated db/db mice). Data is represented as mean± SEM of group size
(n= 7-8).
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Figure 5: (A) Absolute body fat in lean and db/db mice fed chow with and without rosiglitazone. Repeated
measured two way ANOVA analysis with Bonferroni’s posthoc test demonstrated higher body fat in db/db
mice (*p<0.01 vs. lean mice). There was a significant increase in absolute body fat of db/db after treatment
with rosiglitazone (#p<0.001 vs. untreated db/db mice). (B) Absolute lean mass in lean and db/db mice
chow with and without rosiglitazone. Repeated measured two way ANOVA analysis with Bonferroni’s
posthoc did not show any difference in lean mass of db/db and lean mice. Treatment with rosiglitazone did
not affect lean mass in both lean and db/db mice. Data is represented as mean± SEM of group size (n=7-8).
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Figure 6: (A) Total body water in lean and db/db mice fed chow with and without rosiglitazone. Repeated
measured two way ANOVA analysis with Bonferroni’s posthoc test did not demonstrate any difference in
total body water of db/db and lean mice. Treatment with rosiglitazone did not affect total body water in
both lean and db/db mice. (B) Heart weight to body weight ratio in lean and db/db mice chow with and
without rosiglitazone. One way ANOVA demonstrated no significant difference in the ratio of weight of
heart to body weight from db/db mice compared to lean mice. Treatment with Rosiglitazone did not
demonstrate any difference in the ratio of heart weight to body weight ratio of lean and db/db mice. Each
bar represents mean±SEM of group size (n=6-8).
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Figure 7: Immunoblot demonstrating cardiac ACE2 expression in 14 week old lean , lean+ rosiglitazone
(L+R), db/db and db/db +rosiglitazone (db+R) mice after treatment with rosiglitazone. Two
immunoreactive bands were observed at 95 kDa and 30 kDa (n=3).
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Figure 8: Western blot analysis of cardiac ACE2 (95 kDa) expression in lean and db/db mice fed chow
with and without rosiglitazone. One way ANOVA demonstrated significant increase in ACE2 expression
in db/db mice compared to lean mice (*p<0.001). Treatment with rosiglitazone did not affect ACE2
expression in both lean and db/db mice. Each bar represents mean± SEM of group size (n=6-8).
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Figure 9: Western blot analysis of cardiac ACE2 (30 kDa) expression in lean and db/db mice fed chow
with and without rosiglitazone. One way ANOVA did not demonstrate any difference in ACE2 expression
in db/db mice compared to lean mice. Treatment with rosiglitazone did not affect ACE2 expression in both
lean and db/db mice. Each bar represents mean± SEM of group size (n=6-8).
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Figure 10: Immunoblot demonstrating cardiac NEP expression in 14 week old lean (L), db/db and db/db
+rosiglitazone (db+Rosi) mice after 7 weeks of treatment with rosiglitazone. Two immunoreactive bands
were observed at 100 kDa and 65 kDa (n=3).
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Figure 11: Western blot analysis of cardiac NEP (100kDa) expression in lean and db/db mice chow with
and without rosiglitazone. One way ANOVA demonstrated significant decrease in NEP (100kDa)
expression in db/db mice compared to lean mice (*p<0.05). Treatment with rosiglitazone did not show
significant difference in NEP expression of lean control and db/db mice. Each bar represents mean± SEM
of group size (n=6-8).
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Figure 12: Western blot analysis of cardiac NEP (65kDa) expression in lean and db/db mice chow with
and without rosiglitazone. One way ANOVA demonstrated significant increase in cardiac NEP (65 kDa)
expression in db/db mice compared to lean mice (*p<0.01). Treatment with rosiglitazone did not show
significant difference in cardiac NEP expression in lean and db/db mice. Each bar represents mean± SEM
of group size (n=6-8).
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Figure 13: Western blot analysis of cardiac ACE expression in lean and db/db mice chow with and without
rosiglitazone. One way ANOVA demonstrated no significant difference in ACE expression in db/db mice
compared to lean mice. Treatment with rosiglitazone did not show significant difference in ACE expression
of lean and db/db mice. Each bar represents mean± SEM of group size (n=6-8).
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Figure 14: Western blot analysis of cardiac ADAM 17 expression in lean and db/db mice chow with and
without rosiglitazone. One way ANOVA demonstrated a significant increase in ADAM 17 expression in
db/db compared to lean mice (*p<0.001). Treatment with rosiglitazone did not show significant difference
in ADAM 17 expression in both lean and db/db mice. Each bar represents mean± SEM of group size (n=68).
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Figure 15: Representative photomicrographs from Lean, db/db and db/db+ rosiglitazone mice are shown
displaying staining for ACE2 protein (green) in heart sections. The cardiomyocyte nuclei are stained by
DAPI (blue). Original magnification: x400. ACE2 staining was obtained in the epicardium.
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Figure 16: Representative photomicrographs from Lean, db/db and db/db+ rosiglitazone mice are shown
displaying staining for NEP protein (red) in heart sections. The cardiomyocyte nuclei are stained by DAPI
(blue). Original magnification: x400. NEP staining was obtained in the epicardium.
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Figure 17: Representative photomicrographs from Lean, db/db and db/db+ rosiglitazone mice are shown
displaying staining for ADAM 17 protein (green) in heart sections. The cardiomyocyte nuclei are stained
by DAPI (blue). Original magnification: x400. ADAM 17 staining was obtained in the epicardium.
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Figure 18: (A) Blood glucose levels in lean and db/db mice chow with and without pioglitazone. Repeated
measured two way ANOVA analysis with Bonferroni’s posthoc test demonstrated significantly higher
blood glucose in db/db mice (*p<0.001 vs. lean mice). Treatment with pioglitazone significantly attenuated
hyperglycemia in db/db mice (#p<0.001 vs untreated db/db mice). (B) Body weight measurement (g) in
lean and db/db mice chow with and without pioglitazone. Repeated measured two way ANOVA analysis
with Bonferroni’s Posthoc test demonstrated higher body weight in db/db mice (*p<0.001 vs. lean mice).
Treatment with pioglitazone significantly increased body weight in db/db mice (#p<0.001 vs. untreated
db/db mice). Data is represented as mean± SEM of group size (n= 6-7).
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Figure 19: (A) Food intake in (g) in lean and db/db mice chow with and without pioglitazone. Repeated
measures two way ANOVA analysis with Bonferroni’s posthoc test demonstrated higher food intake in
db/db mice (*p<0.001 vs. lean control). Treatment with pioglitazone has no effect on food intake of db/db
and lean mice. (B) Water intake in lean and db/db mice chow with and without pioglitazone. Repeated
measured two way ANOVA analysis with Bonferroni’s posthoc test demonstrated increased water intake
in db/db mice (*p<0.001 vs. lean mice). Treatment with pioglitazone showed a significant decrease in water
intake of db/db mice (#p<0.001 vs untreated db/db mice). Data is represented as mean± SEM of group size
(n= 7-8).
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Figure 20: (A) Absolute body fat in lean and db/db mice chow with and without pioglitazone. Repeated
measured two way ANOVA analysis with Bonferroni’s posthoc test demonstrated higher body fat in db/db
mice (*p<0.01 vs. lean mice). There was a significant increase in absolute body fat of db/db after treatment
with pioglitazone (#p<0.001 vs. untreated db/db mice). (B) Absolute lean mass in lean and db/db mice
chow with and without pioglitazone. Repeated measured two way ANOVA analysis with Bonferroni’s
posthoc did not show any difference in lean mass of db/db and lean mice. Treatment with pioglitazone did
not affect lean mass in both lean and db/db mice. Data is represented as mean± SEM of group size (n=7-8).
48

Total body water (gms/mouse)

20

Lean
Lean+Pioglitazone

15

db/db
db/db+Pioglitazone

10
5
0
0 week

6 week

Heart Wt./Body Wt. (gms)

0.005

Lean
Lean+Pio

0.004

db/db
0.003

db/db+Pioglitazone

0.002
0.001
0.000

Figure 21: (A) Total body water in lean and db/db mice chow with and without pioglitazone. Repeated
measured two way ANOVA analysis with Bonferroni’s posthoc test did not demonstrate any difference in
total body water of db/db and lean mice. Treatment with pioglitazone did not affect total body water in both
lean and db/db mice. (B) Heart weight to body weight ratio in lean and db/db mice chow with and without
pioglitazone. One way ANOVA demonstrated no significant difference in the ratio of weight of heart to
body weight from db/db mice compared to lean mice. Treatment with pioglitazone did not demonstrate any
difference in the ratio of heart weight to body weight ratio of lean and db/db mice. Each bar represents
mean±SEM of group size (n=6-8).
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Figure 22: Immunoblot demonstrating cardiac ACE2 expression in 18 week old lean (L, n=3), db/db (D,
n=3) and db/db +pioglitazone (Dp, n=3) mice after treatment with pioglitazone. Two immunoreactive
bands were observed at 95 kDa and 30 kDa.
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Figure 23: Western blot analysis of cardiac ACE2 (95 kDa) expression in lean and db/db mice chow with
and without pioglitazone. One way ANOVA did not demonstrate any difference in ACE2 expression in
db/db mice compared to lean. Treatment with pioglitazone did not affect expression of ACE2 in db/db mice.
Each bar represents mean± SEM of group size (n=6-8).
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Figure 24: Western blot analysis of cardiac ACE2 (30 kDa) expression in lean and db/db mice chow with
and without pioglitazone. One way ANOVA did not demonstrate any difference in ACE2 expression in
db/db mice compared to lean. Treatment with pioglitazone did not affect ACE2 expression in both lean and
db/db mice. Each bar represents mean± SEM of group size (n=6-8).
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Figure 25: Immunoblot demonstrating cardiac NEP expression in 18 week old lean (L, n=3), db/db (D,
n=3) and db/db +pioglitazone (Dp, n=3) mice after treatment with pioglitazone. Two immunoreactive
bands were observed at 100 kDa and 65 kDa.
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Figure 26: Western blot analysis of cardiac NEP (100 kDa) expression in lean and db/db mice chow with
and without pioglitazone. One way ANOVA did not demonstrate any difference in NEP expression in db/db
mice compared to lean. Treatment with pioglitazone did not affect NEP expression in both lean and db/db
mice. Each bar represents mean± SEM of group size (n=6-8).
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Figure 27: Western blot analysis of cardiac NEP (65 kDa) expression in lean and db/db mice chow with
and without pioglitazone. One way ANOVA demonstrated significant increase in cardiac NEP (65kDa)
expression in db/db mice compared to age-matched lean control mice (*p<0.05).

Treatment with

pioglitazone did not show significant difference in cardiac NEP expression in lean control and db/db mice.
Each bar represents mean± SEM of group size (n=6-8).
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Figure 28: Western blot analysis of cardiac ACE expression in lean and db/db mice chow with and without
pioglitazone. One way ANOVA demonstrated no significant difference in cardiac ACE expression in db/db
mice compared to age- matched lean control mice. Treatment with pioglitazone did not show significant
difference in cardiac ACE expression in lean control and db/db mice. Each bar represents mean± SEM of
group size (n=3).
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Figure 29: Representative photomicrographs from Lean, db/db and db/db+ pioglitazone mice are shown
displaying staining for ACE2 protein (green) in heart sections. The cardiomyocyte nuclei are stained by
DAPI (blue). Original magnification: x400. ACE2 staining was obtained in the epicardium.
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Figure 30: Representative photomicrographs from Lean, db/db and db/db+ pioglitazone mice are shown
displaying staining for NEP protein (red) in heart sections. The cardiomyocyte nuclei are stained by DAPI
(blue). Original magnification: x400. NEP staining was obtained in the epicardium.
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Figure 31: (A) Renal ACE2 activity in 35g of kidney homogenate lean and db/db mice. Assay buffer
contains Tris hydrochloride (0.05M), Zinc Chloride (5mM) and Lisinopril (0.01mM). (Buffer A, pH 7.5)
and Tris, Zinc Chloride, Lisinopril, ZPP(10 µM), Amastatin (5 µM) and Bestatin (5 µM) (Buffer B). MLN4760, a specific inhibitor for ACE2 confirming presence of ACE2. Fluoresence is significantly higher in
db/db mice than lean control mice (*p<0.01).Significant inhibition with MLN-4760 in both lean and db/db
(#p<0.001) confirmed the presence of ACE2. In buffer A, residual fluoresence is observed in lean and
db/db mice after incubation with MLN-4760. In buffer B, fluorescence is inhibited almost completely in
both lean and db/db mice. (B) Renal ACE2 activity in lean and db/db mice based on inhibition in hydrolysis
of substrate after incubation with MLN-4760. Two buffer conditions were used Buffer A and Buffer B. A
significant increase in ACE2 activity is observed in db/db mice compared to lean control in both buffer A
and B (*p<0.001).
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Figure 32: (A) Cardiac ACE2 activity in 35 g of heart homogenate in lean and db/db mice. Two buffer
conditions, Buffer A and Buffer B were used. Heart homogenate from age-matched lean and db/db mice
was used. MLN-4760, a specific inhibitor for ACE2 confirmed presence of ACE2. Significant inhibition
with MLN-4760 in both lean and db/db (#p<0.001) confirmed the presence of ACE2 in both buffer A and
B. In buffer A, residual fluoresence is observed in lean and db/db mice after incubation with MLN-4760
(#p<0.001). In buffer B, fluorescence is inhibited almost completely in both lean and db/db (#p<0.001).
(B) Cardiac ACE2 activity in lean and db/db mice based on inhibition in hydrolysis of substrate after
incubation with MLN-4760. Two buffer conditions were used Buffer A and Buffer B. A significant increase
in ACE2 activity is observed in db/db mice compared to lean control in both buffer A (*p<0.001). In, Buffer
B there was no difference between lean and db/db mice.
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Figure 33: (A) Effect of rosiglitazone on cardiac ACE2 activity in lean and db/db mice in buffer A. Specific
inhibitor MLN-4760 produced significant inhibition in total fluorescence (*p<0.05) in all four groups. (B)
Effect of rosiglitazone on cardiac ACE2 activity in lean and db/db mice based on inhibition in hydrolysis
of substrate after incubation with MLN-4760. A significant increase in ACE2 activity is observed in db/db
mice compared to lean control (*p<0.01). Treatment with rosiglitazone did not have any effect on cardiac
ACE2 activity.
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Figure 34: (A) Effect of rosiglitazone on cardiac ACE2 activity in lean and db/db mice in buffer B. Specific
inhibitor MLN-4760 produced significant inhibition in total fluorescence (*p<0.05) in all four groups. (B)
Effect of rosiglitazone on cardiac ACE2 activity in lean and db/db mice based on inhibition in hydrolysis
of substrate after incubation with MLN-4760. There was no significant difference in ACE2 activity in db/db
mice compared to lean control. Treatment with rosiglitazone did not have any effect on cardiac ACE2
activity.
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Figure 35: (A) Renal NEP activity in 35 g of kidney homogenate from lean and db/db mice. Two buffer
conditions were used, Buffer A and Buffer B. Thiorphan, a specific inhibitor for NEP was used to measure
NEP activity in lean and db/db mice based on inhibition in hydrolysis of substrate after incubation with
Thiorphan. Significant inhibition with Thiorphan in both lean and db/db (#p<0.001) confirmed the presence
of NEP. In buffer A, residual fluoresence is observed in lean and db/db mice after incubation with
Thiorphan. In buffer B, fluorescence is inhibited almost completely in both lean and db/db (#p<0.001). The
fluorescence is brought to almost the baseline after incubation with Thiorphan when buffer B is used. (B)
Renal NEP activity in in lean and db/db mice based on inhibition in hydrolysis of substrate after incubation
with Thiorphan. Two buffer conditions were used, Buffer A and Buffer B. A significant decrease activity
is observed in db/db mice compared to lean control in both buffer A and buffer B (*p<0.001).
63

A
Fluorescence units/ g protein/hr.

1500

Lean
Lean+Thiorphan
db/db

1000

db/db+Thiorphan

#
#
500

#
#

0
Buffer A

Buffer B

B
Fluorescence units/ g protein/hr.

500

Lean
db/db

400
300

*

200

*

100
0
Buffer A

Buffer B

Figure 36: (A) Cardiac NEP activity in 35 g of heart homogenate in lean and db/db mice. Two buffer
conditions were used, Buffer A and Buffer B. Thiorphan, a specific inhibitor for NEP was used to measure
NEP activity in lean and db/db mice based on inhibition in hydrolysis of substrate after incubation with
Thirophan. A significant decrease in NEP activity is observed in db/db mice compared to lean control in
buffer A and buffer B (#p<0.001). Residual fluoresence is observed in lean and db/db mice after incubation
with Thiorphan in buffer A. In buffer B, fluorescence is inhibited almost completely. (B) Cardiac NEP
activity in lean and db/db mice based on inhibition in hydrolysis of substrate after incubation with
Thiorphan. A significant decrease in NEP activity is observed in db/db mice compared to lean control in
both buffer A and buffer B (*p<0.001).
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Figure 37: (A) Effect of rosiglitazone on cardiac NEP activity in lean and db/db mice in buffer A. Specific
inhibitor thiorphan produced significant inhibition (*p<0.05) in all the four groups. (B) Effect of
rosiglitazone on cardiac NEP activity in 35g of heart homogenate in lean and db/db mice based on
inhibiton produced after incubation with MLN-4760. A signiicant decrease in NEP activity is observed in
db/db mice compared to lean control (*p<0.01). Treatment with rosiglitazone did not have any effect on
cardiac NEP activity.
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Figure 38: (A) Effect of rosiglitazone on cardiac NEP activity in lean and db/db mice in buffer A. Specific
inhibitor Thiorphan produced significant inhibition in total fluorescence (*p<0.05) in all four groups. (B)
Effect of rosiglitazone on cardiac NEP activity in lean and db/db mice based on inhibition in hydrolysis of
substrate after incubation with thiorphan. There is a significant decrease in NEP activity in db/db mice
compared to lean control (*p<0.05). Treatment with rosiglitazone did not have any effect on cardiac NEP
activity.
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Figure 39: Effect of pioglitazone on cardiac ACE2 activity in 18wk old lean and db/db mice. Specific
inhibitor thiorphan produced significant inhibition (*p<0.05) in all the four groups. (B) Effect of
pioglitazone on cardiac ACE2 activity in 35g of heart homogenate in lean and db/db mice based on
inhibiton produced after incubation with thiorphan. There was no difference in ACE2 activity is observed
in db/db mice compared to lean control (*p<0.01). Treatment with pioglitazone did not have any effect on
cardiac ACE2 activity.
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Figure 40: (A) Effect of pioglitazone on cardiac NEP activity in 18wk old lean and db/db mice. Specific
inhibitor thiorphan produced significant inhibition in NEP activity (*p<0.05) in all the four groups. (B)
Effect of pioglitazone on cardiac NEP activity in 35g of heart homogenate in lean and db/db mice based
on inhibiton produced after incubation with MLN-4760. There was no difference in NEP activity is
observed in db/db mice compared to lean control (*p<0.01). Treatment with pioglitazone did not have any
effect on cardiac NEP activity.
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V. RESULTS

Specific Aim

To investigate the effect of rosiglitazone on hyperglycemia and cardiac ACE2 and NEP expression.

Physiological and metabolic parameters

To determine the age dependent changes of diabetes and effect of rosiglitazone in db/db diabetic mice, the
following parameters were measured weekly.

(A) Effect of rosiglitazone on blood glucose levels
There was a significant increase in blood glucose levels in 6 week old db/db mice compared to lean normal
mice (*p<0.001,Figure 3A,). Progressive rise in blood glucose levels was observed in db/db mice over 7
weeks of study period. There was no significant change in blood glucose levels in lean control mice over
the 7 weeks of treatments (Figure 3A). Treatment with rosiglitazone normalized blood glucose levels in
db/db mice after 2 weeks of treatment (*p<0.01, Figure 3A,). There was no difference in blood glucose of
lean mice on treatment with rosiglitazone when compared to untreated lean mice (Figure 3A).

(B) Effect of rosiglitazone on body weight
There was a significant increase in the body weight of 6 week old db/db mice compared to lean control
mice (*p<0.01, Figure 3B, ). There was no difference in the body weight of lean mice over 7 weeks of
study treatment. There was a significantly consistent increase in body weight in db/db mice compared to
untreated db/db mice after rosiglitazone (*p<0.01, Figure 3B,). Treatment with rosiglitazone did not have
any effect on the body weight of lean mice when compared to untreated lean mice (Figure 3B).
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(C) Effect of rosiglitazone on food intake
The daily food intake was significantly higher in db/db mice compared to lean mice at 6 weeks of age
(*p<0.001, Figure 4A). There was no difference in food intake of db/db mice after rosiglitazone treatment
(Figure 4A). No difference was observed in food intake of lean mice treated with rosiglitazone compared
to untreated lean mice

(D) Effect of rosiglitazone on water intake
Water intake was significantly higher in db/db mice compared to lean control mice at the age of 6 weeks
(*p<0.001, Figure 4B).There was a significant decrease in water intake of db/db mice after rosiglitazone
treatment compared to untreated db/db mice (#p<0.0001, Figure 4B). No difference was observed in water
intake of lean mice treated with rosiglitazone compared to untreated lean mice (Figure 4B).

(E) Effect of rosiglitazone on absolute body fat
The absolute body fat was increased in db/db mice compared to lean mice (*p<0.01, Figure 5A). There was
a significant increase in absolute body fat of db/db mice after treatment with rosiglitazone compared to
untreated db/db mice (#p<0.001, Figure 5A). No difference was observed in absolute body fat of lean mice
treated with rosiglitazone compared to untreated lean mice (Figure 5A).

(F) Effect of rosiglitazone on absolute lean mass
There was no difference between absolute lean mass of db/db mice and lean mice (Figure 5B). Treatment
with rosiglitazone did not demonstrate any difference in absolute lean mass of db/db mice compared to
untreated db/db mice (Figure 5B). No difference was observed in absolute lean mass of lean mice treated
with rosiglitazone (Figure 5B).

(G) Effect of rosiglitazone on total body water
There was no difference between total body water of db/db and lean mice (Figure 6A). Treatment with
rosiglitazone did not demonstrate any difference in total body water of db/db mice compared to untreated
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db/db mice (Figure 6A). No difference was observed in total body water of lean mice after treatment with
rosiglitazone (Figure 6A).

Plasma hormone and lipid parameters

To assess the effect of hyperglycemia and rosiglitazone treatment on plasma hormonal in mice, plasma
samples were collected at the end of the study from db/db and lean control mice fed normal chow or chow
containing rosiglitazone. The following parameters were analyzed at the Mouse Metabolic Phenotyping
Centre (Cincinnati, OH, USA) as described previously.

(A) Effect of rosiglitazone on plasma insulin
Plasma insulin levels were significantly elevated in db/db mice compared to their age-matched lean mice
(*p<0.05, Table 2). Chronic treatment with rosiglitazone significantly reduced the plasma insulin levels in
db/db mice compared to untreated db/db mice (#p<0.05,, Table 2).

(B) Effect of rosiglitazone on plasma adiponectin
There was a significant increase in the plasma adiponectin levels in db/db mice compared to their agematched lean mice (*p<0.05, Table 2). Chronic treatment with rosiglitazone significantly increased the
plasma adiponectin levels in db/db mice compared to untreated db/db mice (#p<0.05, Table 2).

(C) Effect of rosiglitazone on plasma leptin
There was a significant increase in the plasma leptin levels in db/db mice compared to their age-matched
lean mice (*p<0.05, Table 2). Chronic treatment with rosiglitazone significantly increased the plasma leptin
levels in db/db mice compared to untreated db/db mice (#p<0.05, Table 2).
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(D) Effect of rosiglitazone on plasma glucagon
Glucagon levels were significantly elevated in the plasma in db/db mice compared to their age-matched
lean mice (*p<0.05, Table 2). Chronic treatment with rosiglitazone significantly decreased the plasma
glucagon levels in db/db mice compared to untreated db/db mice (#p<0.05, Table 2).

(E) Effect of rosiglitazone on plasma triglyceride
Plasma triglyceride levels were significantly elevated in db/db mice compared to their age-matched lean
mice (*p<0.05, Table 2). Chronic treatment with rosiglitazone significantly decreased the plasma
triglyceride levels in db/db mice compared to untreated db/db mice (#p<0.05, Table 2).

(F) Effect of rosiglitazone on plasma cholesterol
There was no difference in plasma total cholesterol levels in db/db mice compared to their age-matched
lean mice (Table 2). Chronic treatment with rosiglitazone has no significant effect on plasma cholesterol
levels in db/db mice compared to untreated db/db mice (Table 2).

(v) Effect of rosiglitazone on ratio of heart weight to body weight

To determine any hypertrophic condition in diabetic mice, relative ratio of heart to their body weight was
measured. There was no significant difference in heart weight to body weight ratio in db/db mice compared
to lean mice (Figure 6B). Treatment with rosiglitazone did not demonstrate significant difference in heart
to body weight ratio in both lean and db/db mice compared to untreated mice (Figure 6B).

Cardiac Protein expression of NEP, ACE2, ACE and ADAM 17

To investigate the effect of hyperglycemia and rosiglitazone treatment on protein expression, heart lysates
from 14 week old db/db and age-matched lean mice were studied using western blot analysis.
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(A) Cardiac ACE2
Western blot of cardiac ACE2 expression revealed two immunoreactive bands, an intense band at  95 kDa
and a weak band at  30 kDa in (Figure 7).

(a) Effect of rosiglitazone in cardiac ACE2 (95kDa)

The protein expression of ACE2 (95kDa) was significantly increased in db/db mice compared to lean
control mice (*p<0.001, Figure 8). Treatment with rosiglitazone did not show any difference in expression
of ACE2 (95kDa) in db/db and lean mice (Figure 8).

(b) Effect of rosiglitazone in cardiac ACE2 (30kDa)

There was no difference in ACE2 (30kDa) expression in db/db mice compared to lean control mice
(Figure 9). Treatment with rosiglitazone demonstrated no difference in ACE2 expression (30kDa) in db/db
and lean mice Figure 9).

(B) Cardiac NEP
Western blot analysis of cardiac NEP protein expression revealed two immunoreactive bands, an intense
band at  100 kDa and another band at  65 kDa in (Figure 10).

(a) Effect of rosiglitazone on cardiac NEP 100 kDa

The protein expression of NEP (100 kDa) was decreased in db/db mice compared to lean mice (*p<0.05,
Figure 11). Treatment with rosiglitazone showed no difference in NEP expression (100kDa) in db/db and
lean mice (Figure 11).
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(b) Effect of rosiglitazone on cardiac NEP 65 kDa

The protein expression of NEP (65 kDa) was increased in db/db mice compared to lean mice (*p<0.01,
Figure 12). Treatment with rosiglitazone showed no difference in NEP expression (65kDa) in db/db and
lean mice (Figure 12).

(C) Effect of rosiglitazone on cardiac ACE
There was no difference in expression of ACE in db/db mice compared to lean control mice. (Figure 13).
Treatment with rosiglitazone showed no difference in ACE expression in db/db and lean mice (Figure 13).

(D) Effect of rosiglitazone on cardiac ADAM 17
The protein expression of ADAM 17 increased in db/db mice compared to lean control mice (Figure 14).
Treatment with rosiglitazone showed no difference in ADAM 17 expression in db/db and lean mice (Figure
14).

Immunofluorescence Staining
To investigate the distribution patterns of NEP, ACE2 and ADAM 17 in the heart, immunofluorescence
staining were performed on paraffin embedded heart sections obtained from 14 week old lean and db/db
mice.

(A) Effect of rosiglitazone on cardiac ACE2
Immunostaining was obtained for ACE2 in the epicardium of the heart in lean control, db/db and db/db
mice treated with rosiglitazone (Figure 15)

(B) Effect of pioglitazone on cardiac NEP
Immunostaining was obtained for NEP in the epicardium of the heart in lean control, db/db and db/db mice
treated with rosiglitazone (Figure 16)
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(C) Effect of rosiglitazone on cardiac ADAM 17
Immunostaining was obtained for ADAM17 in the epicardium of the heart in lean control, db/db and db/db
mice treated with rosiglitazone (Figure 17)

Summary
•

Rosiglitazone normalized hyperglycemia in db/db mice and did not affect blood glucose in lean
control mice.

•

Treatment with rosiglitazone significantly increased body weight and body fat in db/db mice.

•

Treatment with rosiglitazone has no effect on body weight and body fat in lean control mice.

•

Two imunoreactive bands for ACE2 and NEP in the heart.

•

Mature ACE2 upregulated in db/db mice suggesting cardioprotective compensatory mechanism.

•

Mature NEP (100 kDa) cleaved to form fragmented NEP (65kDa). This cleavage could be
mediated by ADAM 17 enzyme.

Specific Aim 2

To investigate the effect of pioglitazone on hyperglycemia and cardiac ACE2 and NEP expression.

Physiological and metabolic parameters

To determine the age dependent changes of diabetes and effect of pioglitazone in db/db diabetic mice, the
following parameters were measured weekly.

(A) Effect of pioglitazone on blood glucose levels
There was a significant increase in blood glucose levels in db/db mice compared to lean control mice
(*p<0.001, Figure 18A). Treatment with pioglitazone normalized blood glucose levels in db/db mice
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(#p<0.00, Figure 18A). There was no difference in blood glucose of lean mice treated with pioglitazone
when compared to untreated lean mice (Figure 18A).

(B) Effect of pioglitazone body weight
There was a significant increase in the body weight of db/db mice compared to lean control mice (*p<0.001,
Figure 18B). There was a significant increase in body weight in db/db mice compared to untreated db/db
mice after pioglitazone treatment (#p<0.001, Figure 18B). Treatment with pioglitazone did not have any
effect on the body weight of lean mice when compared to untreated lean mice (Figure 18B).

(C) Effect of pioglitazone on food intake
Daily food intake was significantly higher in db/db mice compared to lean mice (*p<0.001, Figure 19A).
Pioglitazone treatment did not demonstrate any difference in food intake of both db/db and lean mice
(Figure 19A).

(D) Effect of pioglitazone on water intake
Water intake was significantly higher in db/db mice compared to lean control mice (*p<0.001, Figure
19B).There was a significant decrease in water intake of db/db mice after pioglitazone treatment compared
to untreated db/db mice (#p<0.001, Figure 19B). No difference was observed in water intake of lean mice
treated with pioglitazone compared to untreated lean mice (Figure 19B).

(E) Effect of pioglitazone on absolute body fat
The absolute body fat was increased in db/db mice compared to lean control mice (*p<0.01, Figure 20A).
Treatment with pioglitazone demonstrated a significant increase in absolute body fat of db/db mice
compared to untreated db/db mice (#p<0.001, Figure 20A). There was no difference in absolute body fat
of lean mice treated with pioglitazone compared to untreated lean mice (Figure 20A).
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(F) Effect of pioglitazone on absolute lean mass
There was no difference between absolute lean mass in db/db mice and lean mice (Figure 20B). There was
no significant difference in absolute lean mass of both lean and db/db mice after pioglitazone treatment
(Figure 20B).

(G) Effect of pioglitazone on total body water
There was no difference between total body water in db/db mice and lean mice (Figure 21A). There was no
significant difference in total body water of both lean and db/db mice after pioglitazone treatment (Figure
21A).

Effect of pioglitazone on ratio of heart weight to body weight

To determine any hypertrophic condition in diabetic mice, relative ratio of heart to their body weight was
measured. There was no significant difference in heart weight to body weight ratio in db/db mice compared
to lean mice (Figure 21B). There was no significant difference in heart to body weight ratio in db/db and
lean mice after pioglitazone treatment (Figure 21B).

Cardiac Protein expression of NEP, ACE2, ACE and ADAM 17

To investigate the effect of hyperglycemia and pioglitazone treatment on protein expression, heart lysates
from 18 week old db/db and age-matched lean mice were studied using western blot analysis.

(A) Cardiac ACE2
Western blot of cardiac ACE2 expression revealed two immunoreactive bands, an intense band at  95 kDa
and a weak band at  30 kDa in (Figure 22).
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(a) Effect of pioglitazone on cardiac ACE2 (95 kDa)

There was no difference protein expression of ACE2 (95kDa) in db/db mice compared to lean control mice
(Figure 23). Treatment with pioglitazone did not demonstrate a significant difference in protein expression
of ACE2 (95kDa) in db/db mice compared to untreated db/db mice (Figure 23).

(b) Effect of pioglitazone on cardiac ACE2 (30 kDa)

There was no difference in protein expression of ACE2 (30kDa) expression in db/db mice compared to lean
control mice (Figure 24). Treatment with pioglitazone demonstrated no difference in cardiac ACE2
expression (30kDa) in db/db mice compared to untreated db/db mice (Figure 24).

(B) Cardiac NEP
Western blot analysis of cardiac NEP expression revealed two immunoreactive bands, an intense band at
 100 kDa and another band at  65 kDa in (Figure 25).

(a) Effect of pioglitazone on cardiac NEP 100 kDa

There was no difference in protein expression of NEP (100 kDa) in db/db mice compared to lean mice
(Figure 26). Treatment with pioglitazone showed no difference in NEP expression (100kDa) in db/db and
lean mice (Figure 26).

(b) Effect of pioglitazone on cardiac NEP 65 kDa

The protein expression of NEP (65 kDa) was upregulated in db/db mice compared to lean mice (*p<0.05,
Figure 27). Treatment with pioglitazone showed no difference in NEP expression (65 kDa) in db/db and
lean mice (Figure 27).
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(C) Effect of pioglitazone on cardiac ACE
There was no difference in protein expression of ACE in db/db mice compared to lean mice (Figure 28).
Treatment with pioglitazone showed no difference in ACE expression in db/db and lean mice (Figure 28).

Immunohistochemical Staining

To investigate the distribution patterns of NEP and ACE2 in the heart, immnostaining analyses were
performed on heart sections obtained from perfused mice.

(A) Effect of pioglitazone on cardiac ACE2
Immunostaining was obtained for ACE2 in the epicardium of the heart in lean control, db/db and db/db
mice treated with rosiglitazone (Figure 29)

(B) Effect of pioglitazone on cardiac NEP
Immunostaining was obtained for NEP in the epicardium of the heart in lean control, db/db and db/db mice
treated with pioglitazone (Figure 30).

Summary
•

Pioglitazone normalized hyperglycemia in db/db mice and did not affect blood glucose on lean
control mice.

•

Treatment with pioglitazone significantly increased body weight and body fat in db/db mice.

•

Treatment with pioglitazone has no effect on body weight and body fat in lean control mice.

•

Two imunoreactive bands for ACE2 and NEP in the heart.

•

No difference in cardiac ACE2 and NEP expression in 18 week old mice. This suggests that
ACE2 and NEP expression is age-dependent or cyclic in nature.
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Specific Aim 3

To optimize the fluorescence based enzyme activity assay for cardiac and renal ACE2 and NEP. The effect
of rosiglitazone and pioglitazone will also be investigated on cardiac ACE2 and NEP activity. In addition
to studying the effect of hyperglycemia and thiazolidinediones on protein expression of RAS enzymes, it
is important to study the activity with a sensitive and specific assay. We optimized and investigated the
effect of some protease inhibitors on cardiac and renal ACE2 and NEP fluorescent based assays.

Optimization of ACE2 activity

The fluorogenic substrate MCA-APK (Dnp) is commonly used to measure ACE2 activity based on
fluorescent signal produced to indicate activity. However, MCA-APK (Dnp) has been reported to be nonspecific for measuring ACE2. Previous studies from the lab have reported other peptidases like PCP, PEP
might cleave the substrate to produce fluorescent signal (199). We thus have introduced some inhibitors
like Z-prolyl prolinal, amastatin, bestatin in the assay to inhibit interference by PCP, PEP, AP-A and APM. Enzyme activity was then determined by the fluorescence produced in absence and presence of the
ACE2 specific inhibitor, MLN-4760. There are very few reports of ACE2 activity in the heart. We thus
optimized the assay first in kidney lysates and then determine activity in the heart using similar assay
conditions.

Renal ACE2 activity using Tris-HCl buffer (pH 7.4) containing ZnCl2 and Lisinopril (Buffer A)
There was significant inhibition in total fluorescence in both lean (42% inhibition) and db/db (77%
inhibition) kidney samples when incubated with MLN-4760 (*p<0.001, Figure 31A). There was some
background fluorescence generated from lean and db/db samples after incubation with MLN-4760 (Figure
31A). This background indicates the presence of other proteases in the sample. ACE2 activity was measured
as the hydrolysis of substrate in absence and presence of MLN-4760. There was a significant increase in
ACE2 activity in db/db mice compared to lean mice (Figure 31B, *p<0.001).
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Renal ACE2 activity using Buffer A containing ZPP, bestatin and amastatin (Buffer B)
Inhibition in total fluorescence was obtained in both lean (87% fluorescence) and db/db (98% inhibition)
in kidney samples when incubated with MLN 4760 (*p<0.001, Figure 31A). The inhibition produced by
MLN-4760 is thus enhanced by addition of these inhibitors as the total fluorescence was inhibited almost
to the baseline. Moreover, the fluorescence produced in lean mice was lower than that produced in buffer
A (887.757± 53.170 in buffer A vs 281.707± 19.957 in buffer B). ACE2 activity was measured as the
hydrolysis of substrate in absence and presence of MLN-4760. There was a significant increase in ACE2
activity in db/db mice compared to lean mice (*p<0.001, Figure 31B).

Cardiac ACE2 enzyme activity optimization
Addition of the cocktail of the protease inhibitors (ZPP, amastatin, bestatin) to buffer A, improved the
fluorogenic assay and produced more than 95% inhibition of renal ACE2 activity with MLN-4760. We
repeated similar assay conditions for evaluation of cardiac ACE2 activity.

Cardiac ACE2 activity using Tris-HCl (pH 7.4) containing ZnCl2 and lisinopril (Buffer A)
There was significant inhibition in ACE2 fluorescence in both lean (27% inhibition) and db/db (40%) heart
samples when incubated with MLN-4760 (#p<0.001, Figure 32A). High background fluorescence is
produced in both lean and db/db samples after incubation with MLN-4760 (Figure 32A). ACE2 activity
was measured as hydrolysis of substrate in absence and presence of MLN-4760. There was a significant
increase in ACE2 activity in db/db mice compared to lean mice (*p<0.001, Figure 32B, Buffer A).

Cardiac ACE2 activity using Buffer A containing ZPP, bestatin and amastatin (Buffer B)
Inhibition in ACE2 fluorescence by MLN-4760 was significant in both lean (86% inhibition) and db/db
(80% inhibition) heart samples s (#p<0.001, Figure 32A, Buffer B). The inhibition of ACE2 fluorescence
by MLN-4760 was enhanced by addition of protease inhibitors (Figure 32A, Buffer B). Fluorescence
produced in both lean and db/db mice is lower than that those in buffer A. However, there was no difference
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in ACE2 activity db/db mice compared to lean mice after addition of these inhibitors (Figure 32B). This
might suggest the presence of other enzymes in the heart that influence the ACE2 activity assay.

Effect of rosiglitazone using Tris HCl (pH 7.4) , ZnCl2 and Lisinopril (Buffer A)
MLN-4760 demonstrated a significant decrease in fluorescence produced in all the groups (*p<0.05, Figure
33A,). ACE2 activity was significantly increased in db/db mice compared to lean (#p<0.01 vs. lean
control). Cardiac ACE2 activity was not affected in db/db mice after 7 weeks of rosiglitazone treatment
(Figure 33B). There was no difference in ACE2 activity in lean mice treated with rosiglitazone compared
to untreated lean mice (Figure 33B).

Effect of rosiglitazone using buffer A containing ZPP, Bestatin and Amastatin (Buffer B)
MLN-4760 demonstrated a significant decrease in fluorescence produced in all the four groups (*p<0.05,
Figure 34A). Cardiac ACE2 activity was not affected in db/db mice after 7 weeks of rosiglitazone treatment
(Figure 34B). There was no difference in ACE2 activity in lean mice treated with rosiglitazone compared
to untreated lean mice (Figure 34B).

Effect of pioglitazone on cardiac ACE2 enzyme activity in 18 week old mice
In a separate study, we investigate the effect of pioglitazone on cardiac ACE2 in 18 week old mice. We
used Buffer B to avoid interference from other proteases as indicated from above experiments. At 18 week
of age, there was no difference in ACE2 activity between lean and db/db mice (Figure 39). This suggests
that the expression of ACE2 is age-dependent in db/db mice. Treatment with pioglitazone for 10 weeks did
not demonstrate any difference in ACE2 activity (Figure 39).

Optimization of NEP activity

NEP activity is measured with indirect coupled fluorometric method using a Succinyl-ala-ala-phemethoxycoumarine (MCA) substrate. We optimized the NEP fluorogenic assay by introducing inhibitors
for PCP, PEP, AP-A and AP-M to improve specificity and sensitivity of the assay. NEP activity was
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measured by estimating the inhibition in hydrolysis of NEP substrate in presence or absence of the specific
NEP inhibitor, thiorphan. There is limited data in the literature on cardiac NEP activity using this method.
We thus optimized the assay in the kidney lysates.

Renal NEP activity using Tris HCl (pH 7.4), ZnCl2 and Lisinopril (Buffer A)
Thiorphan produced significant inhibition of total fluorescence in lean (56%) and db/db (37%) kidney
samples (*p<0.001, Figure 35A). Background fluorescence is produced in lean and db/db samples even
after incubation with thiorphan (Figure 35A). NEP activity was measured by estimating the inhibition in
hydrolysis of NEP substrate in presence or absence of thiorphan. NEP activity is significantly decreased in
db/db mice compared to lean mice (*p<0.001, Figure 35B).

Renal NEP activity using Buffer A containing ZPP, bestatin and amastatin (Buffer B)
There was significant inhibition in NEP fluorescence by thiorphan in lean (80%) and db/db (51%) kidney
samples (Figure 35A, *p<0.05). Although the inhibition of fluorescence by thiorphan enhanced by addition
of these inhibitors, the background fluorescence in still present (Figure 35A). NEP activity was measured
by estimating the inhibition in hydrolysis of NEP substrate in presence or absence of thiorphan. There was
a significant decrease in NEP activity in db/db mice compared to lean mice in both buffer conditions (Figure
35B, *p<0.001).

Cardiac NEP enzyme activity optimization
Addition of the cocktail of the protease inhibitors (ZPP, amastatin, bestatin) to buffer A, improved the
fluorogenic assay and produced ~30% more inhibition of renal NEP activity with thiorphan. We thus
repeated similar assay conditions for evaluation of cardiac ACE2 activity.

Cardiac NEP activity using Tris-HCl (pH 7.4) containing ZnCl2 and lisinopril (Buffer A)
There was a significant inhibition in NEP fluorescence in lean (51%) and db/db (34%) heart samples when
incubated with thiorphan (*p<0.001, Figure 36A). Background fluorescence was produced in lean and
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db/db samples incubated with thiorphan (Figure 36A). NEP activity was measured by estimating the
inhibition in hydrolysis of NEP substrate in presence or absence of thiorphan. There was a significant
decrease in NEP activity in db/db mice compared to lean mice (*p<0.001, Figure 36A).

Cardiac NEP activity using Buffer A containing ZPP, bestatin and amastatin (Buffer B)
Thiorphan demonstrated significant inhibition of NEP fluorescence in lean (50%) and db/db (22%) heart
samples (*p<0.001, Figure 36A). Thus, the inhibition of total fluorescence by thiorphan was not enhanced
by the addition of the cocktail of the protease inhibitors. There was no significant difference in inhibition
produced by thiorphan in buffer B than buffer A (Figure 36A). NEP activity was measured by estimating
the inhibition in hydrolysis of NEP substrate in presence or absence of thiorphan. There was a significant
decrease in NEP activity in db/db mice compared to lean mice (*p<0.05, Figure 36B).

Effect of rosiglitazone on cardiac NEP activity using Buffer A
Incubation with thiorphan produced significant inhibition of fluorescence in all the four groups (*p<0.05,
Figure 37A). NEP activity was significantly decreased in db/db mice compared to lean (*p<0.01, Figure
37B). Seven weeks of treatment with rosiglitazone has no effect on cardiac NEP activity in db/db mice
(Figure 37B). No difference in NEP activity was seen in lean mice treated with rosiglitazone compared to
untreated (Figure 37B).

Effect of rosiglitazone using Buffer A containing ZPP, Bestatin and Amastatin (Buffer B)
Incubation with thiorphan produced significant inhibition of fluorescence produced in all the four groups
(*p<0.05, Figure 38A). NEP activity was significantly decreased in db/db mice compared to lean (*p<0.01,
Figure 38B) Cardiac NEP activity was not affected in db/db mice after 7 weeks of rosiglitazone treatment
(Figure 38B). No difference in NEP activity was seen in lean mice treated with rosiglitazone compared to
untreated lean mice (Figure 38B).
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Effect of pioglitazone on cardiac NEP enzyme activity in 18 week old mice
In a separate study, we investigate the effect of pioglitazone on cardiac NEP in 18 week old mice. We used
assay buffer containing tris, zinc chloride, lisinopril as addition of inhibitors did not have a significant effect
on the assay results. Thiorphan produced significant inhibition in fluorescence among all the four groups
(*p<0.05, Figure 40A). At 18 week of age, there was no difference in NEP activity between lean and db/db
mice (Figure 40 B). This suggests that the activity of NEP is age-dependent in db/db mice. Treatment with
pioglitazone for 10 weeks did not demonstrate any difference in NEP activity (Figure 40B).

Summary
•

Introduction of protease inhibitors for PCP, PEP, AP-A and AP-M in fluorogenic renal ACE2
activity assay improves specificity towards ACE2 activity.

•

Cardiac ACE2 assay is influenced by other enzymes that confound the results of the assay when
inhibitors are introduced.

•

Renal and cardiac NEP assays are not affected by introduction of protease inhibitors for PCP, PEP,
AP-A and AP-M.

•

Rosiglitazone and pioglitazone have no effect on cardiac ACE2 and NEP activities.
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VI. DISCUSSSION

Leptin receptor deficient db/db mice have been demonstrated to develop hyperglycemia, hyperinsulinemia,
obesity, hypertension and cognitive dysfunction (200;201). Therefore, it is considered to be a good animal
model to study the complication of type 2 diabetes and for screening for new antidiabetic medications. As
expected, in the present study db/db demonstrated hyperglycemia, hyperinsulinemia, obesity and increased
body fat compared to age-matched littermates. Type 2 diabetes syndrome in db/db mice is also
characterized by hyperphagia and polydipsia. Increased food and water intake was demonstrated by db/db
mice in our studies. In addition, plasma hormones e.g. adiponectin, leptin, glucagon, triglyceride were
significantly elevated in db/db mice compared to their littermates. Previous studies in db/db mice
demonstrated normalization of hyperglycemia, water intake, plasma hormone parameters after rosiglitazone
treatment (12). In agreement with our previous study, both rosiglitazone and pioglitazone treatment
normalized hyperglycemia, water intake. Rosiglitazone and pioglitazone are insulin sensitizers and thus
treatment lead to a decrease in plasma insulin, leptin, glucagon and triglycerides in db/db mice.. In addition,
adiponectin a hormone secreted from adipose tissue as a modulator for fatty acid oxidation is reduced with
rosiglitazone in db/db mice (202). Treatment with both rosiglitazone and pioglitazone demonstrated
significant increase in body weight in db/db mice. Increase in body mass index has been associated with
increased risk of heart failure in both female and male patients (203). Several reports suggest that fluid
retention after thiazolidinediones treatment leads to pressure overload on the heart and thus increases risk
of heart failure (204). Our studies demonstrated no difference in total body water in mice treated with both
rosiglitazone and pioglitazone between lean and db/db mice. There was no difference in lean body mass of
in both lean and db/db mice after treatment. In addition, rosiglitazone and pioglitazone treatment has no
effect on blood glucose and body weight of lean control mice
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Our previous study showed decreased renal NEP protein expression in db/db mice (205) . We have also
shown that physical exercise training of db/db mice decreased hyperglycemia and increased renal NEP
protein expression (206). We evaluated the cardiac expression of NEP in db/db mice. In addition, the effect
of rosiglitazone and pioglitazone on cardiac NEP protein was also evaluated. Western blot analysis in heart
lysates for NEP demonstrated two immunoreactive bands at 100kDa and 65 kDa in contrast with one only
band in the kidney. To our knowledge this is the first report of two immunoreactive bands in the heart. This
experiment was repeated more than 4 times and we obtained similar results in 14 and 18 week old mice.
Since there was only one band in the kidney and two in the heart, this suggests that the expression of NEP
is organ specific. The specificity of the NEP antibody was determined in WT and NEP KO mice. There
was no band for NEP in the NEP-KO. This suggest the multiple bands obtained in the heart lysate is not
due to technical artifacts. The 100 kDa immunoreactive band of NEP shows significant downregulation in
14 weeks old db/db mice compared to lean control. In the second study, there was no significant difference
in the 100 kDa immunoreactive band of NEP heart lysates from 18 week old db/db mice compared to lean
control lean. According to reports in various organs, this band represents the fully mature form of NEP
(207;208). The degree of insulin resistance and hyperglycemia is worse by time. db/db mice follow an agedependent progression in diabetes, with starts with early serve insulin resistance which is followed later by
a defect in insulin secretion which will result in profound hyperglycemia. It has been shown before that
there are age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from
db/db mice (209). The difference in the data between 14 and 18 weeks might suggest that the expression
of NEP in the heart might be age-dependent.

NEP is responsible for degradation of Ang I in addition to natriuretic peptides (210). Thus, standalone
therapy with NEP inhibitors nullify the potential benefits of increased natriuretic peptides through increased
levels of circulating Ang II (211-213). Despite there being no apparent benefits of NEP inhibition alone,
combined NEP inhibition and ACE inhibition has demonstrated a decrease in blood pressure and cardiac
hypertrophy in hypertensive rats (214;215). We have reported earlier an increase in plasma ACE activity
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and Ang II content in db/db mice (193;212;213). Downregulation in NEP could be thus in response to
increased Ang II levels in the body as a cardioprotective measure.

Interestingly, the 65 kDa band of NEP shows significant upregulation in db/db mice compared to lean
control in both studies. This might suggest the possibility of the mature form (100kDa) of NEP being
cleaved to form the 65kDa fragment in the heart. Thus, the downregulation in 100kDa band of NEP can be
explained. It is required to ascertain the identity of both the bands as NEP. Amino acid sequence and mass
spectrometric analysis can be performed in samples after separation of the two bands on a polyacrylamide
gel. It is not known whether both forms of NEP in the heart are active, MALDI or SELDI mass
spectrometric enzyme analysis could be performed after separation of the bands. There are numerous
possibilities for the interaction of both forms of NEP with each other. Both forms might be enzymatically
active or one of them might be more active than the other. It is also possible to speculate synergistic activity
of both the forms.

Previous study demonstrated that treatment with rosiglitazone upregulates renal NEP expression and
activity in db/db mice (205). Rosiglitazone did not affect the cardiac expression of both forms of NEP
(100kDa and 65KDa). In contrast, pioglitazone treatment demonstrated a downregulation in the expression
of both the bands (100kDa and 65kDa). This differential effect of rosiglitazone and pioglitazone
demonstrates a distinction in the action of both compounds on the same target. Several studies using
rosiglitazone demonstrated either no effect or an increased risk of heart failure. In contrast, pioglitazone
has been associated with a mild reduction in stroke and MI risk (216). It can be speculated

that

downregulation of cardiac NEP by pioglitazone is associated with cardiovascular benefit.

We also evaluated the cardiac ACE2 protein expression and activity in db/db mice. In addition, the effect
of rosiglitazone and pioglitazone on cardiac ACE2 was also evaluated. Western blot analysis of cardiac
ACE2 demonstrated two immunoreactive bands at 95 kDa and 30 kDa in contrast with only one band (95
kDa) in the kidney. Similar to NEP expression in the heart, expression of ACE2 is also organ specific, there
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are two distinct bands in the heart versus one in the kidney. The specificity of the ACE2 antibody was
determined in WT and ACE2 KO mice. There was no band for ACE2 in the ACE2-KO. This suggest the
multiple bands obtained in the heart lysate are not due to technical artifacts. The 95 kDa band of ACE2 is
upregulated in db/db group compared to lean control in 14 week old mice. In 18 week old mice, there was
no significant difference between 95kDa form of ACE2 in lean and db/db. Renal expression of ACE2 has
been reported to be significantly higher in 8 week compared to 30 week old db/db mice (193). The results
in heart samples thus suggest a similar age-dependent alteration in cardiac ACE2 expression. Upregulation
of ACE2 could be a possible cardioprotective measure by the body. The 30 kDa band for ACE2
demonstrated no difference in ACE2 expression between lean and db/db mice in both the studies. Similar
to NEP bands, identity of both forms of cardiac ACE2 could be confirmed with amino acid sequencing and
mass spectrometric analysis after separation of the two bands on a polyacrylamide gel. MALDI or SELDI
analysis of both forms of ACE2 could confirm whether both the bands of ACE2 are active.

The use of intramolecularly quenched fluorogenic substrate are widely used to measure enzyme activity in
biological fluids (217). MCA-APK-Dnp is a fluorogenic substrate which is commonly used for
measurement of ACE2 activity (218). Fluorescence is produced by the 7-methoxycoumarine (MCA) moiety
after cleavage at Pro-Lys site separates the quenching 4-diniteophenyl (Dnp). However, there were reports
that this fluorescence produced represents 56% of total enzymatic activity of ACE2 at pH 7.5 (219). It has
been suggested that fluorescence by such artificial substrates may be a result of peptidases other than ACE2
and thus produce inaccurate estimation of enzyme activity (220). Enzymes like prolyl endopeptidase (PEP),
prolyl carboxypeptidase (PCP), aminopeptidases A and M might cause cleavage of the fluorogenic substrate
(220). Alternative methods such as mass spectrometry based assays, use natural substrates and are more
selective and specific (220). However, these methods are not easily accessible and are cost-prohibitive.
Since, NEP and ACE2 activities were not evaluated before in db/db mice, we aimed to reevaluate the
selectivity and specificity of the fluorogenic assay for renal and cardiac samples.
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Ours and other results showed increased renal ACE2 activity in db/db and Akita mouse models of diabetes
(11;12). ACE2 activity was first performed in kidney lysate obtained from 18 week old mice using. TrisHCl buffer (pH 7.4) containing 0.15M NaCl, Zinc chloride and the selective ACE inhibitor, lisinopril
(Buffer A). Specific ACE2 inhibitor, MLN-4760 was used to validate the specificity of the assay.
Significant inhibition by MLN-4760 was observed in both lean and db/db mice (Figure 13A). As expected
renal ACE2 activity was significantly increased in db/db mice compared to lean control. However,
fluorescence was not completely inhibited in lean and db/db mice in the presence of MLN-4760 (Buffer A,
Figure 13A). This suggest that other proteases in addition to ACE2, cleaves MCA-APK-Dnp and produce
fluorescence. The percentage of fluorescence inhibited by MLN-47 in lean and db/db mice was significantly
enhanced (95%) in the presence of specific inhibitors for PCP, PEP, APA and APM. This demonstrated
that addition of inhibitors improves the specificity of the assay. Moreover, the total fluorescence produced
in lean mice using buffer B was significantly reduced compared that produced using buffer A. The
fluorescence produced in db/db mice was similar in both buffer conditions. This might suggest that the
activity of PCP, PEP, AP-A and M are suppressed in db/db mice compared to lean. It’s noteworthy to
mention that regardless of buffer conditions used, the renal expression of ACE2 was increased in db/db
mice compared to lean. Whereas, in the heart there was different result in ACE2 activity with change in
buffer conditions.

We next aimed to apply the same assay procedure in heart lysates. Inhibition produced by MLN-4760
incubation was significant in both lean and db/db mice. This inhibition was significantly reduced compared
to that observed in the kidney samples. This suggests that there is much more ACE2 activity in the kidney
than the heart. Background fluorescence was produced in the heart samples after MLN-4760 incubation
suggesting interference of other enzymes in the assay. There was an increase in cardiac ACE2 activity in
db/db mice compared to lean. Addition of PCP, PEP, AP-A and AP-M inhibitors produced significantly
lower fluorescence than buffer A. This suggests that enzymes like PCP, PEP, AP-A and AP-M are involved
in cleavage of substrate in the heart. Surprisingly, the fluorescence in db/db mice in buffer B was less than
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lean mice in contrast to that observed in buffer A. There was no difference in cardiac ACE2 activity between
lean and db/db mice. ACE2 activity in 18 week old mice demonstrated no difference between lean and
db/db mice. This result corresponded to the western blot results for cardiac ACE 2 expression. Thus,
alternative enzyme assay methods like MALDI mass spectroscopic analyses should be used for reliable
measurement of ACE2 activity in heart lysates. Rosiglitazone treatment did not affect renal ACE2
expression and activity in db/db mice (12). In agreement with these data, Our results did not demonstrate
any difference in cardiac ACE2 activity in db/db and lean mice treated with rosiglitazone and pioglitazone.

We also aimed to optimize the cardiac NEP fluorogenic assay. Similar buffer conditions like the ones used
in ACE2 activity optimization assay were used. Previous studies using fluorogenic substrate demonstrated
a decrease in renal NEP activity in db/db mice compared to lean (221). Assay was optimized in kidney
lysates form 17 week old lean and db/db mice using inhibitors for PCP, PEP, AP-A and AP-M. The assay
buffer containing Tris, NaCl, ZnCl2 and lisinopril was used. The NEP inhibitor ,thiorphan, was also used
to confirm the NEP specificity in this assay. Thiorphan produced significant inhibition in both lean and
db/db mice. Using buffer B, fluorescence was decreased in both lean and db/db mice. Inhibition with
thiorphan was greater in buffer B conditions than buffer A. Renal and cardiac NEP activity was decreased
in db/db mice in both buffer conditions compared to lean control. Overall fluorescence was decreased in
buffer B compared to buffer A. NEP activity was decreased in db/db mice compared to lean in 14 week old
mice.

Treatment with rosiglitazone in db/db mice demonstrated increase in renal NEP activity (205). Cardiac NEP
activity is not affected in db/db mice with rosiglitazone treatment. However, treatment with pioglitazone
demonstrated a decrease in NEP activity in 18 week old mice. This suggests a difference between actions
of rosiglitazone and pioglitazone. Decrease in cardiac NEP by pioglitazone might have cardioprotective
effect through the subsequent rise of natriuretic peptides. It would be interesting to investigate whether this
effect of pioglitazone is through PPAR- agonism or through its effect in normalizing hyperglycemia.
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Further mechanistic studies on cardiomyocytes can be conducted to study the mechanism of action for its
direct action on NEP.

One thing to note in measurement of enzyme activity is the presence of multiple bands of ACE2 and NEP
in heart lysate as demonstrated by western blot experiments. The identity and activity of individual forms
of both cardiac ACE2 and NEP needs to be confirmed with amino acid sequencing and mass spectroscopy.
The activities could be attributed to the presence of either of the forms or might be a synergistic effect. As
mentioned, a MALDI technique for assessing activities of each of the forms is required.

We have previously reported the direct ability of ADAM 17 protein in cleaving and shedding membrane
bound ACE2 (222). Studies in endothelial cell line demonstrate ADAM 17 mediated cleavage of NEP to
form a soluble non-membrane bound form (223). Renal expression of ADAM 17 was upregulated in db/db
mice in previous studies (12). Western blot analysis revealed that cardiac ADAM 17 is upregulated in db/db
diabetic mice. ADAM 17 knockdown by RNA interference prevented development of cardiac hypertrophy
and fibrosis in Ang II induced hypertensive rat model (224). ADAM 17 is upregulated with TNF-α in
patients with decline in left ventricular systolic function (225). ADAM 17 is upregulated in patients with
advanced congestive heart failure (226). ADAM 17 inhibition attenuated development of left ventricular
hypertrophy (227). As mentioned before, there were two bands for NEP in the heart with two distinct forms.
The mature band (100kDa) was downregulated in db/db mice and a fragment band of (65kDa) was
upregulated (Figure 9 and 10). ADAM 17 could be responsible for the cleavage of the fully mature band
with increased formation of cleaved NEP (65kDa).
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VII.

CONCLUSION

To the best of our knowledge this is the first time cardiac ACE2 and NEP expression has been studied in
db/db diabetic mice. Our study demonstrated a novel finding that there are two immunoreactive bands for
ACE2 and NEP in the heart as opposed to one in the kidney. Upregulation in cardiac ADAM 17 might
cause cleavage of mature NEP to form fragmented form in diabetic conditions. ACE2 upregulation in the
heart could be a cardioprotective measure against hyperglycemic insult. Assessment of enzyme activity of
NEP and ACE2 should however, be performed using more sophisticated methods like MALDI mass
spectrometric methods.
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VIII.

APPENDICES
APPENDIX A

Renal and cardiovascular dysfunction in db/db diabetic mice is associated with increased cardiac
angiotensin converting enzyme 2 (ACE2) and neprilysin (NEP)
Rucha Fadnavis, Meenasri Kumbaji, Salim El-Amouri, Nadja Grobe and Khalid M. Elased
Boonshoft School of Medicine, Wright State University, Dayton, OH
The prevalence of diabetic kidney disease (DKD) has increased in the recent decades and is considered one
of the main causes of ESRD. DKD is also a major risk factor for cardiovascular diseases. Proteinuria is now
widely accepted as an independent risk factor for cardiovascular morbidity and mortality. The renin
angiotensin system (RAS) plays an important role in regulating both the renal and cardiovascular systems.
The deleterious actions of Ang II are antagonized by Ang (1-7), which is generated by ACE2 and NEP.
ACE2 and NEP are multifunctional enzymes and their shedding in the urine have emerged as early
biomarkers for DKD. ACE2 has been shown to have renoprotective and cardioprotective role in diabetic
mice. In addition, a combination of AT1 receptor blockade and NEP inhibition, Sacubitril-Valsartan is used
for management of heart failure. The aim of this study was to investigate whether shedding of urinary ACE2
and NEP could be a predictor of cardiovascular disease and index of intra cardiac ACE2 and NEP status in
db/db diabetic mice. Radio-telemetry was used to measure blood pressure. Control and diabetic db/db mice
(8 weeks) were treated with pioglitazone (20mg/Kg/day) for 10 weeks. Western blot, immunostaining and
RAS enzyme assays were used to study renal, urinary and cardiac protein expression and activities. db/db
mice are normotensive at the ages of 8-12 weeks. There were no significant differences in cardiac ACE2
and NEP between db/db and control mice. However, at 18 weeks, db/db mice developed albuminuria and
hypertension. In addition, at this age there was a significant increase in urinary and cardiac ACE2, NEP
expression and activity. Pioglitazone treatment of db/db diabetic mice normalized hyperglycemia and
attenuated albuminuria. In addition, pioglitazone increased expression and activity of cardiac ACE2
whereas it decreased expression and activity of cardiac NEP compared to untreated db/db mice.Pioglitazone
treatment could be used as a renoprotective and cardioprotective since it attenuated albuminuria, increased
cardiac ACE2 and decreased cardiac NEP. Increased urinary ACE2 and NEP could be used to predict
alteration of cardiac RAS status and possible risk of cardiovascular diseases.
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APPENDIX B
Effect of pioglitazone on the shedding of urinary angiotensin converting enzyme (ACE) 2 and
neprilysin (NEP) in db/db mice and their role as urinary biomarkers for diabetic kidney disease
Meenasri Kumbaji1, Rucha Fadnavis1, Salim El-Amouri1, Mohammad G. Saklayen2, Khalid M. Elased1,
Nadja Grobe1.
1. Boonshoft School of Medicine, Wright State University, Dayton, OH
2. Dayton VA Medical Center, Dayton, OH,

Diabetic kidney disease (DKD) is one of the major causes of end-stage renal disease. Angiotensin (Ang) II
is the major biological active peptide of the renin angiotensin system. Elevated levels of Ang II contribute
to initiation and progression of DKD. The actions of Ang II could be antagonized by its conversion to the
vasodilator Ang (1-7), partly generated by the action of ACE2 and NEP. Although there is an emergence
of some urinary biomarkers such as angiotensinogen, kidney injury molecule-1 (KIM-1) and neutrophil
gelatinase-associated lipocalin (NGAL), there is still a need for new early biomarkers for DKD. The aim is
to investigate the effect of hyperglycemia on urinary albuminuria, ACE2, NEP and KIM-1 and to test the
hypothesis that ACE2 and NEP can be used as early biomarkers for DKD. 8 weeks old control and db/db
diabetic mice were subjected to pioglitazone treatment (20 mg/kg/day) for 10 weeks. Metabolic and renal
parameters were measured. Urine was collected for the evaluation of ACE2, NEP, KIM-1 protein
expression and RAS activity. At 7 weeks old, there was no significant difference in urinary albumin, NEP
and KIM-1 between db/db and control mice. However, western blot showed a significant increased
shedding of urinary ACE2 fragment (60KDa and 70kDa immunoreactive bands) in db/db mice compared
to controls. Although there was a prominent immunoreactive band for NEP in control mice at 9 weeks,
there was no detectable immunoreactive band for ACE2. After the development of albuminuria in older
db/db mice (9-17week), there was a significant increase of full length (95KDa) and fragment of ACE2,
NEP (90kDa) and KIM-1 (75KDa) compared to control mice. Urinary NEP and ACE2 activities
significantly increased in 17 weeks db/db mice compared to controls. Pioglitazone normalized
hyperglycemia and attenuated urinary albumin, glucose and ACE2 shedding. However, it has no effect on
urinary NEP and KIM-1. In db/db diabetic mice, increased shedding of enzymatically active ACE2
precedes albuminuria. Depletion of tubular renal ACE2, NEP, could lead to accumulation of Ang II, with
concomitant development of microalbuminuria. Urinary ACE2 and NEP could be used as biomarkers for
DKD.
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